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Severe acute respiratory syndrome (SARS) was the first pestilence in the 21st 
century, with more than 8,000 infectious cases including 774 fatalities in over 29 
countries. Because of its essential role in virus replication, the SARS coronavirus 
main protease (Mpro) is considered to be one of the top targets for anti-SARS drug 
design. Although similar to picornavirus 3C proteases, SARS-CoV Mpro has a 
chymotrypsin fold that hosts the entire catalytic dyad, and it has acquired a unique 
C-terminal extra domain with an unknown function.  
In this thesis, we aim at understanding the regulatory role of this extra domain in 
the catalysis of the SARS-CoV main protease. We demonstrate that: 1) The extra 
domain contributes to the dimerization of SARS-CoV Mpro, switching the enzyme 
from the inactive form (monomer) to the active form (dimer), as analyzed by protein 
dissection, Dynamic Light Scattering (DLS) and size-exclusion chamotography; 2) 
Four regions (residues 288-290, 291, 284-286 and 298-299) in the extra domain are 
critical for the enzyme dimerization and catalysis of SARS-CoV Mpro, forming a 
nano-scale channel passing through the central region of the enzyme, as revealed by 
site-directed mutagenesis, DLS, nuclear magnetic resonance (NMR) spectroscopy and 
enzymatic activity assay; 3) Mutating the C-terminal residue Arg298 to Ala allows the 
switching of SARS-CoV Mpro from dimer to monomer in solution, as measured by 
analytical ultracentrifuge (AUC). A crystallography study further reveals that in the 
monomeric form, the SARS-CoV Mpro mutant is irreversibly inactivated because its 
catalytic machinery becomes frozen in a collapsed state, characterized by the 
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formation of a short 310-helix within the chameleon catalytic loop; 4) Ala mutations in 
the STI loop located at the dimer interface between the two extra domains are able to 
increase the kcat value of SARS-CoV Mpro in the enzyme kinetics assay. The 
crystallographic study shows that these Ala mutations affect the interface inducing a 
rigid-body re-orientation of the protomers if compared to that observed for 
SARS-CoV Mpro crystallized at low pH, mimicking the high-pH conformation of 
SARS-CoV Mpro reported to have a higher catalytic potential than that at a low pH. 
Together, these results reveal a new and critical role of the C-terminal extra domain in 
the dimerization and catalysis of the SARS-CoV Mpro. These may imply a general 
function of the C-terminal extra domains in all coronavirus main proteases.  
The most important results of our study reveal a novel strategy for the design of 
specific inhibitors against coronavirus main protease. The ideal inhibitor would be 
one that can affect the conformation of the dimer interface of the proteases and at the 
same time convert the main proteases’ active site into a catalytically incompetent 
conformation. Such a bifunctional inhibitor should be a highly competent drug 
candidate for SARS and other coronavirus-related diseases. Last but not least, our 
study sheds new light on the general principle of enzyme evolution, where the 
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 Chapter 1 - Severe Acute Respiratory Syndrome 
 
1.1. Severe Acute Respiratory Syndrome (SARS)  
Severe Acute Respiratory Syndrome (SARS) was the first pandemic in the 21st 
century, initially appearing as an atypical pneumonia in China’s Guangdong Province 
in November 2002. It then spread rapidly to 32 countries and regions including 
Vietnam, Singapore, Thailand, Taiwan, and Canada, and resulted in more than 8,000 
infected people, including 774 fatalities (Figure 1.1) (SARS Investigative Team 2003). 
In response to the emergence of SARS, the World Health Organization (WHO) 
broadcast a global alert and travel advice from March 15, 2003 (Parry 2003). In the 
SARS affected countries, a heightened vigilance, exit and entry screening for 
international travelers, isolation of affected persons, and quarantine of their close 
contacts, were all applied to monitor and limit this new and highly transmissible 
infection disease (Bell 2004). Fortunately, the epidemic was eliminated in several 
months for unknown reasons, although a handful of laboratory-infected cases and 
other scattered cases were later reported (Peiris et al. 2004;Skowronski et al. 2005).  
Because of its high mortality rate and unique methods of transmission, SARS did 
not only affect public health, but also caused a huge economic loss of US$ 30–140 





Figure 1.1 - Number of probable cases of SARS (Figure adapted from 
WHO website on May 14, 2003) 
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1.1.1. Transmission and symptoms 
The transmission of SARS is mainly through the respiratory droplets generated 
during close contact with very ill people. During hospital care, a high infection rate 
among physicians and nurses was found to be linked with aerosol-generating 
procedures (intubation, nebulization, bronchoscopy, suction, and ventilation) that 
facilitate virus transmission. No reported case was derived from a vertical or blood 
transmission (Christian et al. 2004). 
The average time between contact with patients and the appearance of the major 
symptom, fever, was six days. Early diagnosis was difficult because the initial 
symptoms of SARS (high fever, myalgia, and cough) are similar to that of the 
common cold. In most cases, a clinical case ascertainment was used as a definition for 
the surveillance of SARS (Lee et al. 2003;So et al. 2003).  
 
1.1.2. Etiology and therapy 
Several infectious pathogens, such as metapneumovirus or chlamydia, were 
initially identified in the specimens of some affected patients, and these were 
consequently considered as the potential etiologic agents of SARS. However, only a 
new coronavirus was later found to fulfill Koch’s postulates for SARS causation 
(Peiris et al. 2003;Fouchier et al. 2003). Most importantly, inoculation of the 
coronavirus from the specimens of the affected patients can cause a SARS-like 
phenomenon in nonhuman primates (Ksiazek et al. 2003;Kuiken et al. 2003;Rota et al. 
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2003). As a result, WHO announced on April 16, 2003 that this new coronavirus was 
an infectious agent of SARS. To distinguish it from the other coronaviruses, this new 
coronavirus was named the SARS coronavirus (SARS-CoV).  
Despite extensive research on the SARS-CoV in the last five years, neither a 
vaccine nor an effective therapy has yet been made available. The treatment for SARS 
is only based on broad-spectrum antiviral agents and immunomodulating agents. 
Therefore, there is an urgent need to design new effective therapeutic agents against 
the SARS-CoV. 
 
1.2. SARS-CoV genome and life cycle  
The SARS coronavirus (SARS-CoV) is an enveloped, positive-strand RNA virus, 
belonging to a new group of Coronaviridae, which is famous for the largest RNA 
genome known to date (27~31Kb) (Rota et al. 2003;Lai, Cavanagh 1997). 
Coronaviruses can be divided into three serologically distinct groups: two groups of 
predominantly mammalian coronaviruses, and one group of avian coronaviruses. 
There are three coronaviruses—human coronavirus 229E (HCoV-229E, Group I), 
human coronavirus OC43 (HCoV-OC43, Group II), and human coronavirus NL63 
(HCoV-NL63, Group I)—that have been identified and reported to have caused 
illnesses (upper respiratory tract infections or diarrhea) in humans (Chouljenko et al. 




1. Attachment & Entry 
2. Uncoating & 
RNA release 
3. Translation 
4. Polyprotein processing 
5. Assembly of replicase complex 
6. Synthesis of sub-genomic mRNA 










The genome of the SARS-CoV is 29 Kb, encoding 14 open reading frames 
(ORFs). The two large ORFs (pp1a and pp1b) encode proteins that are required for 
viral genome replication and transcription. The rest of the ORFs encode S, M, N, and 
E proteins, besides other proteins (Marra et al. 2003;Ruan et al. 2003). 
The viral life cycle, as shown in Figure 2.1, has the following stages. 1) The 
attachment of the SARS-CoV virion to the host cell via a receptor-mediated 
interaction. The N-terminal residues of the SARS-CoV spike protein bind to the 
cellular receptor angiotensin-converting enzyme 2 (ACE2) (Li et al. 2003). This 
interaction eventually leads to the cell entry, followed by 2) the uncoating 
(nucleocapsid removal) and the release of the viral RNA into the cytoplasm. In the 
next event, 3) translation of the positive RNA produces two large polyproteins, pp1a 
(450kD) and pp1b (750kD). 4) These two polyproteins perform self-proteolysis to 
release some structural and non-structural components with the help of viral proteases. 
These components are subsequently involved in 5) the formation of a replicase 
complex associated with the ER membrane. 6) This action directs the synthesis of a 
negative-stranded RNA, which in turn serves as a template for a nested set of 
subgenomic positive-stranded mRNAs encoding all the other viral proteins (S, M, N 
and E, etc.) through a unique discontinuous transcription mechanism. Thereafter, 7) 
the assembly of new virions begins with the structural components, and ensues in 
encapsidation. The new infectious virion is possibly enveloped via ER budding and is 
finally 8) released from the cell (Masters 2006).  
 25 
 
1.2.1. Polyprotein processing 
Similar to other coronaviruses, the main ORF of the SARS-CoV is translated into 
two large polyproteins, pp1a and pp1b (Blakeney et al. 2003). Upon proteolysis, the 
two polyproteins release a group of functional subunits that are required for viral 
genome replication and transcription. The proteolysis of the polyproteins is mediated 
by two viral cysteine proteases, one with a chymotrypsin-like fold, and the other with 
a papain-like fold. The chymotrypsin-like fold protease is called “main protease, 
Mpro” to indicate its dominant role in the polyprotein proteolysis, or “3C-like 
protease, 3CLpro” referring to its similarity to the picornavirus 3C protease (Thiel et 
al. 2003;Yang et al. 2003). 
The SARS-CoV Mpro is responsible for eleven cleavage sites located at the 
central and the C-terminal regions of the polyproteins (Fan et al. 2004;Fan et al. 2005). 
Proteolysis of the polyproteins begins with a cis-cleavage (intra-molecular) to 
self-release the main protease, and is followed by the trans-cleavage (inter-molecular) 
to produce other proteins (Lin et al. 2004;Shan et al. 2004). The completion of the 
polyprotein proteolysis is very important for the life cycle of the SARS coronavirus. 
Any disruption in the proteolysis can significantly slow down the viral amplification 
in humans.  
 
1.3. SARS-CoV main protease (Mpro) 
Because of its predominant role in the polyprotein proteolysis, the SARS-CoV 
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Mpro is considered to be one of the top targets for anti-SARS drug design (De 2006). 
It was believed that the tertiary structure of the SARS-CoV Mpro is very critical for 
the inhibitor designed to combat this protease. Therefore, only three days after the 
release of the SARS coronavirus genomic sequence, the first homology model of the 
SARS-CoV Mpro was reported, based on the crystal structure of the human 
coronavirus 229E (HCoV-229E) main protease, and a related porcine transmittable 
gastroenteritis coronavirus (TGEV) main protease (Figure 3.1), which show 40% and 
44% sequence identity to the SARS-CoV Mpro, respectively (Anand et al. 2002). The 
first high resolution crystal structure of SARS-CoV Mpro was reported by Rao’s 
group in November, 2003 (Yang et al. 2003) (Figure 4.1).  
The gene encoding the SARS-CoV Mpro was highly conserved among the 
coronavirus family. The coding region (from nucleotide 9984 to 10901 on ORF1a and 
ORF1ab) has been cloned into various expression vectors, and a large amount of the 
protease can be obtained for biochemical and biophysical studies (Gao et al. 2003). 









                     1                                     40 
SARS-CoV Mpro    (1) SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDTVYCPR 
HCoV229E-Mpro    (1) AGLRKMAQPSGFVEKCVVRVCYGNTVLNGLWLGDIVYCPR 
    TGEV-Mpro    (1) SGLRKMAQPSGLVEPCIVRVSYGNNVLNGLWLGDEVICPR 
                     41                                    80 
SARS-CoV Mpro   (41) HVICTAEDMLNPNYEDLLIRKSNHSFLVQAGNVQLRVIGH 
HCoV229E-Mpro   (41) HVIAS-NTTSAIDYDHEYSIMRLHNFSIISGTAFLGVVGA 
    TGEV-Mpro   (41) HVIAS-DTTRVINYENEMSSVRLHNFSVSKNNVFLGVVSA 
                     81                                   120 
SARS-CoV Mpro   (81) SMQNCLLRLKVDTSNPKTPKYKFVRIQPGQTFSVLACYNG 
HCoV229E-Mpro   (80) TMHGVTLKIKVSQTNMHTPRHSFRTLKSGEGFNILACYDG 
    TGEV-Mpro   (80) RYKGVNLVLKVNQVNPNTPEHKFKSIKAGESFNILACYEG 
                     121                                  160 
SARS-CoV Mpro  (121) SPSGVYQCAMRPNHTIKGSFLNGSCGSVGFNIDYDCVSFC 
HCoV229E Mpro  (120) CAQGVFGVNMRTNWTIRGSFINGACGSPGYNLKNGEVEFV 
    TGEV Mpro   (120) CPGSVYGVNMRSQGTIKGSFIAGTCGSVGYVLENGILYGV 
                     161                                  200 
SARS-CoV Mpro  (161) YMHHMELPTGVHAGTDLEGKFYGPFVDRQTAQAAGTDTTI 
HCoV229E Mpro  (160) YMHQIELGSGSHVGSSFDGVMYGGFEDQPNLQVESANQML 
    TGEV Mpro   (160) YMHHLELGNGSHVGSNFEGEMYGGYEDQPSMQLEGTNVMS 
                     201                                  240 
SARS-CoV Mpro  (201) TLNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYE 
HCoV229E Mpro  (200) TVNVVAFLYAAILNGCTWWLKGEKLFVEHYNEWAQANGFT 
    TGEV Mpro   (200) SDNVVAFLYAALINGERWFVTNTSMSLESYNTWAKTNSFT 
                     241                                  280 
SARS-CoV Mpro  (241) PLTQDHVDILGPLSAQTGIAVLDMCAALKELLQNGMNGRT 
HCoV229E Mpro  (240) AMNG--EDAFSILAAKTGVCVERLLHAIQV-LNNGFGGKQ 
    TGEV Mpro   (240) ELSS--TDAFSMLAAKTGQSVEKLLDSIVR-LNKGFGGRT 
                     281                    306 
SARS-CoV Mpro  (281) ILGSTILEDEFTPFDVVRQCSGVTFQ 
HCoV229E Mpro  (277) ILGYSSLNDEFSINEVVKQMFGVNLQ 




Figure 3.1 – Main protease sequence alignment among SARS-CoV, HCoV-229E 
and TGEV  























Figure 4.1 Superimpose of the Mpros of HCoV 229E (green) (1P9U), 
TGEV (red) (1P9S) and SARS-CoV (blue) (1UJ1). 
The catalytic dyad (His 41-Cys 145) is shown in spheres.  
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1.3.1. Biophysical and catalytic properties of SARS-CoV Mpro 
 
The SARS-CoV Mpro is a buffer-soluble protein, where the protein concentration 
can reach at least 10 mg/ml without aggregation (Yang et al. 2003). In solution, the 
protease adopts a well-defined α-helix-and-β-sheet-mixed secondary structure, and an 
irreversible two-stage thermo-unfolding profile, with the midpoint Tm of 61oC, 
indicating a highly cooperative thermodenaturation (Fan et al. 2004).  
Catalysis of the SARS-CoV Mpro can be affected by many factors, including pH, 
temperature, reducing agent (Dithiothreitol, DTT), and ionic strength (sodium 
chloride). Plotting the enzymatic activity as a function of pH exhibits a bell-shaped 
curve with a pH optimum of 7.0~8.0. The optimum temperature for catalysis is about 
42o C. The enzymatic activity increases gradually from 25 to 42o C, and decreases 
rapidly from 42 to 45o C due to the thermo-denaturation of the protease. DTT is 
especially important to maintain the enzymatic activity of the protease, since it keeps 
the side chain of the catalytic residue Cys reduced. However, too high a concentration 
of DTT (>5mM) can lead to a reduction in enzymatic activity. Interestingly, the 
enzymatic activity of the protease is highly sensitive to ionic strength, where the 
enzymatic activity decreases dramatically in the presence of 1M sodium chloride (Fan 
et al. 2004;Graziano et al. 2006a;Kuo et al. 2004).  
 
1.3.2. Overall tertiary structure and geometry of SARS-CoV Mpro 
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More than twenty tertiary structures of the SARS-CoV Mpro and its complexes 
with various inhibitors have been solved by X-ray crystallography (Table 1.1), and 
deposited in the Protein Data Bank (PDB) (Yang et al. 2003;Xue et al. 2007;Lee et al. 
2005;Lee et al. 2007;Hsu et al. 2004;Hsu et al. 2005a;Lu et al. 2006;Tan et al. 
2005;Zhang et al. 2007;Zhou et al. 2006). In crystal, the SARS-CoV Mpro forms a 
symmetric dimer with two protomers (named ‘A’ and ‘B’) oriented at almost 90°. 
Each protomer consists of three domains, two β-barrel domains (domains I and II), 
and one helical domain (domain III) (Figure 5.1). The two β-barrel domains (residue 
12–172) create a chymotrypsin-like fold with six antiparallel β-stands at each domain, 
while the C-terminal helical domain (residue 200–306) contains five helices forming a 
large globular cluster. The helical domain is linked to the two β-barrel domains by a 
long loop (residue 173–199). At the N-terminus, the first seven residues, forming the 
N-finger, are inserted into the cleft between domain II and domain III of the parent 
protomer, and interact with domain III of the opposite protomer. In this thesis, the two 
β-barrel domains are also called ‘the catalytic folds,’ to indicate their predominant 
role in the protease catalysis. The helical domain is unique in the coronavirus main 
protease, and it had no clear function at the time we started this project. However, 
several truncation studies on TGEV Mpro and IBV Mpro have suggested that the 
integrity of this domain would be important for the catalysis of the coronavirus 
proteases (Anand et al. 2002;Ng, Liu 2000;Ziebuhr et al. 1997;Lu, Denison 1997).  
The structures of the coronavirus main proteases are conserved among the 






Table 1.1 The SARS-CoV Mpro structures as well as the Mpros of HCoV 
229E, TGEV and IBV 
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SARS-CoV, HCoV 299E and TGEV shows a root mean square (rms) deviation 
below 2 Å for all 300 Cα atoms of the molecules (Figure 4.1). Regions containing the 
most variations are the helical domain and the connective loop (Anand et al. 2003).  
 
1.3.3. Catalytic dyad of SARS-CoV Mpro 
Catalysis of the SARS-Cov Mpro is mediated by a catalytic dyad consisting of a 
catalytic nucleophile, Cys145, and a base residue, His41. The importance of His41 
and Cys145 in the catalysis has been shown by Ala mutagenesis (Huang et al. 2004). 
The catalytic dyad locates at the interface between domain I and domain II, where 
residue His41 comes from domain I, and the residue Cys145 comes from domain II 
(Figure 5.1). The reactive atom of Cys145 (SG) is just about 3.2 Å away from the 
proton reservoir atom (ND2) of His41, and is coplanar with the imidazole ring of 
His41 (Lee et al. 2005). Interestingly, in the high resolution crystal structures of the 
SARS-CoV Mpro, a water molecule is entrapped by Asp187 and His41 (Xue et al. 
2007). The role of this water molecule in the catalysis of the main protease is still 
under debate. One of the hypotheses suggests that this water molecule shields the side 
chain of Asp187 from the catalytic dyad of the SARS-CoV Mpro. In a molecular 
dynamic simulation study, the SARS-CoV Mpro has been observed that the water 
molecule is squeezed out by the side chain of His41, the imidazole ring of His41 
moves toward Asp187 and a stable hydrogen bond is formed between atom ND1 of 
His41 and atom OE2 of Asp187 within 2.79 Å. In this model, the contact between 
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His41 and Asp187 suggests the existence of a catalytic triad (His41, Cys145 and 
Asp187) that may have a higher catalytic efficiency than that of the dyad (Zheng et al. 
2007). Another hypothesis proposes that this water molecule serves as a hydrolytic 
water molecule in an acyl-enzyme intermediate hydrolysis (Lee et al. 2007;Yin et al. 
2007).  
It is important to note that the catalytic cysteine residue functions differently in 
the two different classes of cysteine proteases. In papain-like cysteine proteases, there 
is a thiolate-imidazolium ion pair between the catalytic Cys and His. The thiolate ion 
is stabilized by the positive end of the permanent dipole of a helix. There is no effect 
from the water molecule in the ion pair mechanism. Meanwhile, in chymotrypsin-like 
cysteine proteases including SARS-CoV Mpro, the catalytic cysteine acts as a 
nucleophile, its partner histidine acts as a general base, and the water molecules play 
an important role in this base mechanism.  
To understand whether SARS-CoV Mpro is a papain-like or a chymotrypsin-like 
cysteine protease, Cys145 of this protein was experimentally substituted with a Ser 
residue. If it was a papain-like cysteine protease, the Mpro should have lost its activity 
totally, since the substituted Ser cannot form a thiolate-imidazolium ion pair with 
His41. In fact, the mutated Mpro remains active even though its enzymatic activity is 
low, 3% compared to the wild type. This indicates that there is no 
thiolate-imidazolium ion pair in the SARS-CoV Mpro, and so, this protein is not a 
papain-like cysteine protease. In addition, the enzymatic activities of both the native 







Figure 5.1 Structure of SARS-CoV Mpro (A) and the active site (B) 
The protomer A is colored in red, and the protomer is colored in blue. The blue 
dot near H41 is water molecule. 
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and D2O, in comparison to the activity in the solution of H2O only. This means 
that the H2O molecules are essential for the catalysis of the SARS-CoV Mpro. This is 
a property of chymotrypsin-like cysteine proteases, since H2O is required for efficient 
hydrolysis of these enzymes. Thus, the SARS-CoV Mpro belongs to the class of 
chymotrypsin-like cysteine proteases (Huang et al. 2004).  
Hence, the wealth of knowledge on the catalytic mechanisms of serine proteases 
may be useful to explain the enzymatic properties of the SARS-CoV Mpro (especially 
because cysteine proteases have not been studied as extensively as have serine 
proteases). In general, catalysis of serine proteases occurs in two sequential steps that 
involve two tetrahedral intermediate states. In the first (acylation) step, the 
nucleophilic oxygen of Ser attacks the amide carbonyl of the peptide substrate to form 
the first tetrahedral intermediate, in which a covalent bond is formed between the 
substrate carbonyl carbon atom and the reactive serine oxygen atom. This 
intermediate breaks down to an acyl-enzyme complex, and releases a free C-terminal 
product fragment. In the second (deacylation) step, a water molecule or some other 
acyl-accepting nucleophile attacks the acyl-enzyme, forming the second tetrahedral 
intermediate (Figure 4.1) followed by the release of the N-terminal fragment (Figure 
6.1). The nitrogen of histidine acts as a general base to activate serine as a nucleophile 
by accepting a proton, and subsequently acts as a general acid with a hydrolytic water 
molecule, donating a proton to the carbon of the N-terminal peptide (Huang et al. 
2004). A schematic representation of the hydrolytic mechanism of the serine protease 











Figure 6.1 - Schematic representation of hydrolytic mechanism of serine 
proteases  
a. The enzyme-substrate complex. 
b. The first tetrahedral structure. The nucleophilic oxygen of Ser attacks the amide 
carbonyl of the peptide substrate. 
c. The assigned acyl-enzyme intermediate. The C-terminal of substrate detaches.  
d. The second tetrahedral structure.  










1.3.5. Substrate binding regions of SARS-CoV Mpro  
In general, the amino acid residues flanking the protease cleavage sites are 
denoted from the N to the C terminus as follows: -P3-P2-P1↓ P1’-P2’-P3’- . The 
corresponding substrate binding site is therefore, denoted as –S3-S2-S1 ↓ 
S1’-S2’-S3’- (Schechter, Berger 1967). 
All the native substrates of the SARS-CoV Mpro have an absolute-conserved Gln 
residue at position P1. S1, the first substrate binding site of SARS-CoV Mpro, is 
composed of His163, Phe140, Met165, Glu166 and His172. Upon binding, Gln-P1 
forms two hydrogen bonds with His163 and Glu166. Atom NE2 of His163 donates a 
proton to atom OE1 of Gln-P1 to form a stable hydrogen bond, while atom OE2 of 
Glu166 accepts a proton from atom NE2 of Gln-P1, to form another stable hydrogen 
bond. The two hydrogen bonds drag the side chain of Glu166 together with the 
imidazole ring of His163, leaving atom NE2 of His163 just about 7 Å away from 
atom OE2 of Glu166. The side chains of His163 and Glu166 form a “tooth” 
conformation, keeping the carboxamide side chain of Gln-P1 in the S1 subsite. The 
specific interaction of Gln-P1 with Glu166 and His163 and the “tooth” structure 
explain why Gln is absolutely conserved at the P1 site (Figure 5.1) (Zheng et al. 
2007;Lee et al. 2005). 
The hydrophobic side chain of Leu at position P2 is well accommodated by the 
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second substrate binding site of SARS-CoV Mpro (S2 site) (Zheng et al. 2007). In the 
S2 subsite, residues Tyr54, Thr47, Asp48, Leu164, and Met165 form a hydrophobic 
pocket which is suitable for a bulk hydrophobic side chain residue (Figure 5.1). The 
peptide substrates with Phe or Val replacement in the P2 position are also favorable 
for the hydrolysis by the SARS-CoV Mpro, with reduced activity, while the other 
hydrophobic residues, such as Met and Ile, are intolerant in the P2 position. This 
demonstrates the important role of S2 site’s hydrophobic pocket in the substrate 
specificity determination (Fan et al. 2005;Chu et al. 2006). 
The P1’ is also an important position for the binding specificity of the SARS 
Mpro substrates. This position often contains Ser, a conserved small side chain 
residue. The S1’ pocket, consisting of residues Glu47 and Asp48, has a very small 
void, so that bulky side-chain residues, such as Glu, Asp or Pro, cannot fit in this 
position. Only small aliphatic residues, such as Ser, Ala and Gly, are favored in this 
position (Chu et al. 2006). 
Substrate residues P3–P5 form a β-strand that is anti-parallel with strand 
(164–167) and loop 189–191 of the SARS-CoV Mpro. Residues Ala-P4 and Val-P3 
form two hydrogen bonds with Met165 and Gln189 of the Mpro, while residue 
Phe-P3’ is involved in a hydrophobic interaction with the Mpro. Together, these 
substrate residues, Phe-P3’, Val-P3, Ala-P4, and Ser-P5, provide a stronger interaction 
between the protease and the substrate, enhancing the catalytic reaction that is 
contributed primarily by the core sequence (-P2-P1-P1’-) (Fan et al. 2005). 
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1.3.6. Conformational change of active site and substrate binding region 
S1 
The substrate binding and catalysis of the SARS-CoV Mpro is not always granted 
by the conformation of its active site and the substrate binding site S1. In some 
situations, such as at low pH (6.0 and below), or in the presence of the N-terminal 
additional residues, the active site and the S1 substrate binding region of the 
SARS-CoV Mpro adopt a conformation that is not suitable for either substrate binding 
or catalysis. Problems that can make SARS-CoV Mpro catalytically incompetent 
include: 1) a shiftment of the phenyl ring in Phe140 outward, ruining the S1 substrate 
binding site, and 2) a dramatic rearrangement of the big loop (residues 137–145) 
(Figure 5.1), leading to the collapse of the oxyanion hole (Yang et al. 2003;Xue et al. 
2007).  
To maintain the active site and S1 substrate binding region in a catalytically 
competent conformation, the protein must maintain two critical interactions: 1) the 
aromatic interaction between the imidazole ring of His163 and the phenyl ring of 
Phe140, and 2) the interaction between Phe140 and Ser1 from the opposite protomer. 
In the absence of these two interactions, the active site and the S1 substrate binding 
region will lose their competent conformations (Lee et al. 2005).  
Interestingly, the binding of a native substrate to the SARS-CoV Mpro can rescue 
the active site and the S1 substrate-binding region from the catalytically incompetent 
conformation as the critical interactions are recovered by Gln-P1. This indicates that 
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the substrate binding mechanism of the SARS-CoV Mpro follows an induced-fit 
model (Lee et al. 2005;Lee et al. 2007). 
1.3.7. Catalysis of SARS-CoV Mpro as a pH-dependent mechanism  
Enzymatic assays of the SARS-CoV Mpro have shown that the catalysis of this 
protein is dependent on pH. The optimum pH was found to be 7.0~8.0. Either a lower 
or higher pH will lead to a reduction in the enzymatic activity. In particular, pH 
affects the conformation of the catalytic dyad. At a low pH, the imidazole ring of His 
is protonated, so that the interaction between the imidazole ring of His and the thiol 
side chain of Cys is weakened, resulting in the lower activity of SARS-CoV Mpro. At 
pH 7.0, the imidazole ring of His is deprotonated, attracting a proton on the thiol side 
chain of Cys and subsequently, the sulfur atom of Cys145 is activated. Therefore, the 
catalytic dyad is fully functional at this pH  (Lee et al. 2007;Tan et al. 2005).  
Besides, the hydrophobic interaction between the phenyl ring of Phe140 and the 
imidazole ring of His163 was also proposed to be an important factor in the 
pH-dependent catalysis of the SARS-CoV Mpro. In this aromatic interaction, one or 
two hydrogen atoms (with partial positive charge) on the phenyl ring of Phe140 are 
positioned near the central region of the imidazole ring of His163 (with partial 
negative charge). At low pH, near or below the pkα1 of His163 (such as pH 6.0), the 
ND1 atom of His163 is protonated in a large portion of the Mpro. Thereby, a positive 
charge is introduced onto the imidazole ring of His163, disfavoring the aromatic 
interaction with the positive charge Phe140. In contrast, at high pH (7.6), the 
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imidazole ring of His163 is deprotonated in a large portion of the Mpro. A greater 
negative charge is thus created, and a stronger interaction results, with the phenyl ring 
of Phe140. Thus, in the pH range of 7.0–8.0, this aromatic interaction helps maintain 
the main proteases in the catalytically competent conformation, whereas at a low pH 
(such as 5.9–6.6), a loss of the aromatic interaction will result in the catalytically 
incompetent conformation of the main proteases (Lee et al. 2007). 
Last but not least, the pH-dependent regulation of SARS-CoV Mpro catalysis is 
also determined by the interactions between Ser1 from the opposite protomer, and 
Phe140 from the parent protomer. These interactions are certainly important in 
maintaining the catalytic loop in the catalytically competent conformation. At a low 
pH, ranging from 5.9–6.6, with the disruption from the additional N-terminal residues 
inherited from an expression vector, the interactions between Phe140 and Ser1 from 
the opposite protomer are weakened, causing several changes: 1) in the crystal 
structure of SARS-CoV Mpro, the B-factors of the catalytic loop (residues 137 to 145) 
exceed the average B-factor of the entire protease, and 2) the active site partially 
adopts a catalytically incompetent conformation, associated with the disorder of Ser1 
and Gly2 from the opposite protomer. At a high pH, ranging from 7.6–8.0, even with 
the disruption from the additional N-terminal residues, the interactions between 
Phe140 and Ser1 from the opposite protomer are favarable  and thus, the active site 
and the S1 substrate binding region are in a catalytically competent conformation (Lee 
et al. 2007). However, the detailed mechanism modulating the flexibility of Ser1 
under different pH conditions remains elusive. 
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1.3.8. Dimerization of SARS-CoV Mpro and impact on enzyme catalysis 
The SARS-CoV Mpro forms a dimer in solution, as well as in crystal form. 
Dimerization is very important for the catalysis of the SARS-CoV Mpro, although 
other 3C proteases that share the similar chymotrypsin-fold with Mpro are active as a 
monomer (Fan et al. 2004;Anand et al. 2002). It is believed that only the dimer form 
of the SARS-CoV Mpro is active, whereas the monomer form is inactive. Although 
this hypothesis is well-known, there has not been any direct experimental evidence to 
prove that the monomer form of the SARS-CoV Mpro is inactive or weakly active, 
and why the dimerization of the SARS-CoV Mpro is essential for catalysis has yet to 
be explored. 
 
1.3.8.1. Environmental factors affecting dimerization of SARS-CoV Mpro 
Dimerization of the SARS-CoV Mpro is affected by many factors, such as 
protease concentration, pH, and ionic strength. The proportion of Mpro dimer 
increases linearly with the increase of protein concentration (from 1nM to 10μM), 
resulting in a concurrent increase in enzymatic activity. The dimerization is reversible, 
and the transition between the monomeric state and the dimeric state is very fast 
(Graziano et al. 2006b).  
pH is an important factor affecting the dimerization of the SARS-CoV Mpro. 
Plotting the monomer-dimer association constant with the pH value results in a 
bell-shaped curve, with the highest dimer portion at pH 7.4, similar to the enzymatic 
activity-pH plot (Fan et al. 2004).  
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Ionic strength also plays an important role in the dimer formation of the 
SARS-CoV Mpro. In the presence of 4M sodium chloride, a major portion of the 
SARS-CoV Mpro exists as monomers in solution, whereas in the absence of sodium 
chloride, a major portion of the SARS-CoV Mpro is in dimer form. This indicates that 
electrostatic forces critically contribute to the dimerization of the SARS-CoV Mpro 
(Chou et al. 2004).  
 
1.3.8.2. Monomer-dimer association constant of SARS-CoV Mpro 
Since the monomer-dimer equilibrium plays an important role in the catalysis of 
the SARS-CoV Mpro, and any agents that affect the dimerization could be the 
potential inhibitors of the SARS-CoV Mpro, the equilibrium constant has been 
extensively studied with various techniques, such as analytical size exclusion 
chromatography, HPLC-based enzymatic activity assay, fluorescence resonance 
energy transfer (FRET) enzymatic activity assay, isothermal titration calorimetry 
(ITC), analytical ultracentrifugation (AUC), and chemical cross linking and 
small-angle X-ray scattering (Chou et al. 2004;Fan et al. 2004;Graziano et al. 
2006b;Kuo et al. 2004;Hsu et al. 2005a;Hsu et al. 2005b;Kuang et al. 2005;Barrila et 
al. 2006;Tan et al. 2005). However, there is about a 105-fold discrepancy among the 
equilibrium constants reported by different groups, perhaps due to variations in 
measurement conditions, and the intrinsic properties of different techniques. Recently, 
Graziano et al. used three different techniques, including enzymatic kinetics, chemical 
cross linking and small-angle X-ray scattering, to determine the monomer-dimer 
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association constant of the SARS-CoV Mpro. Their results indicate that the KD value 
is in the range from 5.3–12.7μM (Graziano et al. 2006b). 
 
1.3.8.3. Critical structural features for dimerization of SARS-CoV Mpro  
Information on the structure of the dimerization interface is very useful for the 
inhibitor designed to combat the SARS-CoV Mpro, because dimerization is an 
indispensable characteristic of this protein (Shi et al. 2004).  
We were the first to successfully identify domain III as an important factor for 
dimerization of the SARS-CoV Mpro (as described in the Results section). The 
importance of SARS-CoV Mpro’s structure on its dimerization was subsequently 
elaborated by other groups. Chou et al. demonstrated that residue Glu290 forms an 
important salt bridge with residue Arg4 from the opposite protomer. Mutating any of 
these two residues to Ala significantly affects the dimerization equilibrium constant 
and the catalysis of the SARS-CoV Mpro. Scientists from the same group showed that 
the N-finger (residue 293–306) of the SARS-CoV Mpro is also critical for 
dimerization. The truncated protease shows little enzymatic activity in the kinetic 
assay, and its KD value is significantly higher than that of the full-length protein as 
measured by analytical ultracentrifuge (Chou et al. 2004;Hsu et al. 2005b).  
Another residue from the N-finger (residue Met6) was reported by Wei et al to 
play a role in dimerization and catalysis of the SARS-CoV Mpro. The Mpro in which 
Met6 is mutated to Ala shows lower enzymatic activity, and a higher monomer-dimer 
equilibrium constant in comparison with the native Mpro under the same conditions. 
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It is believed that the hydrophobicity of the long side chain of Met6 is essential for the 
dimerization and the catalysis of the Mpro (Wei et al. 2006).  
Interestingly, the dimerization of the SARS-CoV Mpro is modulated not only by 
the residues around the dimer interface, but also by some remote residue such as 
Ser147, which is about 9 Å away from the dimer interface. Undeniably, Ser147 
locates near the catalytic dyad, but it is not involved in either substrate binding or the 
catalytic machinery. The point mutation Ser147Ala destroys the catalytic capability of 
the protease by locking the mutant protease in a monomeric form. Hence, residue 
Ser147 is involved in the group of residues that maintain the dimerization of the 
SARS-CoV Mpro. Apparently, this group is not limited to the dimer interface area, 
but is much larger, including some long-range cooperative interactions. Removal of a 
hydroxyl group from Ser147 may somehow break one or more long range cooperative 
interactions, blocking the dimerization as well as the catalytic capability (Barrila et al. 
2006).  
 
1.4. Design of specific inhibitors against SARS-CoV Mpro 
  As the SARS-CoV Mpro is considered to be a very important target for 
anti-SARS drug design, intensive time and research has been devoted to studying this 
protease. The search for inhibitors against SARS-CoV Mpro can be conducted in 
several ways, including 1) high throughput screening (HTS) of chemical compounds 
(in vitro and in silicon), 2) the modification of the known 3C protease inhibitors based 
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on the structural similarity between the SARS-CoV Mpro and the other 3C proteases, 
3) the rational design of peptidic inhibitors, using substrates as the starting point, and 
4) the identification of inhibitors blocking the dimerization of the SARS-CoV Mpro.  
 
1.4.1. High throughput screening (HTS)  
To systematically identify active inhibitors blocking the catalysis of the 
SARS-CoV Mpro, a great variety of compounds have been screened by several 
high-throughput methods.  
 
1.4.1.1. In vitro high throughput screening 
Since the early 1990s, high throughput screening technologies have established 
their essential role in the drug discovery process. Millions of chemical compounds 
have been tested by SARS-CoV Mpro kinetic assays.  A numbers of nonpeptide 
inhibitors of the SARS-CoV Mpro have been discovered, such as 
3-quinolinecarboxylic Acid, (2-(2-nitrophenyl)-1,3-diphenyl-imidazolidine (Kao et al. 
2004), cinanserin (Chen et al. 2005a), and metal-conjugated compounds (Hsu et al. 
2004).  
 
1.4.1.2. In silicon high throughput screening 
In recent years, structure-based virtual screening (in silicon) has been developed 
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as a new high throughput screening technique. This technique makes use of available 
information on protein tertiary structures and of advanced computational power to 
predict potential drugs. Millions of compounds can be tested by docking into the 
inhibitor-binding pocket of the target protein in silicon. After multiple steps in the 
calculations, the highest evaluated potential active compounds are selected for 
subsequent experimental validation. In the next step, the analogs can be generated 
based on the candidates that were successful in the first round. These are selected by 
docking them into the inhibitor-binding pocket once again. After several rounds of 
prediction and validation, the most active compounds may be identified.  
In the SARS-CoV Mpro inhibitor design, the active site pocket is the most 
favorite inhibitor-binding pocket. Lu et al. discovered two μM-inhibitors which bind 
uncovalently to the active site of the SARS-CoV Mpro from a chemical database 
containing more than 50,000 compounds (Lu et al. 2006). Dooley et al. identified 
another μM-inhibitor based on the computer-predicted model of the SARS-CoV Mpro 
(Dooley et al. 2006). Tsai et al. also revealed a new family of the SARS-CoV Mpro 
inhibitors through the structure-base virtual screening (Tsai et al. 2006).  
 
1.4.2. Derivatives of 3C protease inhibitors 
Based on the similarity of the SARS-CoV Mpro and other 3C proteases in their 
chymotrypsin-like catalytic fold, several successful inhibitors against 3C proteases 
have been shown to exhibit certain binding activity and inhibitory effects on the 
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SARS-CoV Mpro. One of these inhibitors was derived from a rhinovirus 3C protease 
inhibitor by Yang et al (Yang et al. 2005). Another series of inhibitors against the 
SARS-CoV Mpro was derived by Zhou et al., based on isatin, an inhibitor of the 
human rhinovirus-2 protease. One of these derivatives shows a good inhibition effect 
on the SARS-CoV Mpro with an IC50 of 0.37 μM (Zhou et al. 2006).  
 
1.4.3. Peptidic inhibitors 
Another approach to design inhibitors against the SARS-CoV Mpro is to create 
derivatives of the protease’s native substrate.  
 
1.4.3.1. Substrate-like aza-peptide epoxide 
Aza-peptide epoxide (APE) is a new class of inhibitors for cysteine proteases. 
Each APE has an aza-peptide component, with an epoxide moiety attached to the 
carbonyl group of P1 residue. The aza-peptide component resembles a peptide, except 
that the Cα atom of the P1 residue is replaced by a nitrogen atom to form an 
aza-amino acid residue. The specificity of APE is mainly determined by the side chain 
of the P1 residue, and is partially dependent on the tuning of epoxide, which is 
controlled by the substituent on the epoxide C2 atom. In aza-peptide, the 
electrophilicity of the carbonyl C atom of the P1 residue is reduced, due to trigonal 
planar geometry. Thereby, the carbonyl group of the P1 residue resists the 
nucleophilic attack. The mechanism that APE uses to inhibit their target peptidases 
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irreversibly is based on a nucleophilic attack of the catalytic Cys S atom to one of the 
two epoxide carbon atoms (C2 or C3) of APE. This leads to the opening of the 
conformational strained epoxide-ring and the formation of a covalent bond between 
the Cys S atom and the attacked APE atom (Ekici et al. 2004;Powers et al. 2002). 
Remarkably, Lee et al. designed an Aza-peptide with aza-glutamine (AGln) at the 
P1 position to mimic the S1 specificity of the SARS-CoV Mpro for Gln. This APE 
shows a good inhibitory effect on the SARS-CoV Mpro, where kinact/Ki=1900(+400) 
M-1s-1. Also, the inhibitory mechanism was well demonstrated by a crystal structure of 
the SARS-CoV Mpro with the APE. The Aza-peptide, 
Cbz-Leu-Phe-AGln-(S,S)EPCOOEt, binds to the SARS-CoV Mpro at the active 
pockets of the two protomers. The binding does not cause any major structural change: 
the overall RMSD between the unbounded and the bounded SARS-CoV Mpro is only 
0.37Å. The S atom of Cys145 forms a 2.01 Å C-S bond with the epoxide C3 atom. 
The epoxide ring of APE opens, leading to the hydrogen bond formation bridging the 
hydroxyl group of the ring C2 atom to the OD atom of Asn142 in SARS-CoV Mpro, 
and to the P2-Phe carbonyl O atom of APE. The side chain of AGln-P1 is 
accommodated in the oxyanion hole of the SARS-CoV Mpro. Thus, the aza-peptide 
component of APE binds to the two protomers of the SARS-CoV Mpro in a 
substrate-like manner (Lee et al. 2005;Lee et al. 2007).  
 
1.4.3.2. Substrate-analog inhibitors 
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Substrate is usually a good starting point for inhibitor design, due to its binding 
affinity and specificity with the protease. Yang et al. designed two substrate-analog 
inhibitors, N1 and N2, based on a substrate analog Cbz-STLQ-trans-α,β-unsaturated 
ethyl ester, which mimics the SARS-CoV Mpro substrate residues P4-P1. Due to the 
high structural similarity between the coronavirus main proteases, these inhibitors 
have shown a μM-inhibitory effect not only on the SARS-CoV Mpro, but also on the 
main proteases from HCoV-229E, TGEV, MHV, FIPV, and IBV. Inhibitor N1 binds to 
the SARS-CoV Mpro active site in an extended conformation. The backbone of N1 
formed an anti-parallel sheet with residue 164–168 of the long stand eII on one side, 
and with residues 189–191 of the long loop, linking the catalytic domain and the extra 
helical domain, on the other side (Yang et al. 2005). 
 
1.4.4. Inhibitors blocking dimerization of SARS-CoV Mpro 
The dimer interface of the SARS-CoV Mpro is an attractive target for the 
inhibitor designed to combat the SARS-CoV Mpro. Since the N-finger plays an 
important role in the dimerization and the catalysis of the SARS-CoV Mpro, a peptide 
that mimics eight residues of the N-terminal is able to block dimerization, and thereby, 
inhibit the catalysis of the SARS-CoV Mpro with a Ki of 2.2mM. This is the first 
approach to design inhibitors targeting the dimeric interface of the SARS-CoV Mpro. 
However, more experiments are required to understand this inhibitory mechanism 






Chapter 2 - Aims of the Present Study 
The ultimate goal of this project is to understand the unique enzymatic 
mechanism of the SARS-CoV main protease as controlled by the extra helical 
domain, as a fundamental background for anti-SARS drug design.  
Based on the fact that the SARS-CoV Mpro has an extra helical domain in 
addition to the catalytic fold, which shares a similar topology to the picornavirus 3C 
protease, we hypothesize that this extra domain may contribute a unique property to 
the SARS-CoV Mpro. To demonstrate this hypothesis, our specific aims are: 
1) To study the contribution of the extra helical domain to the dimerization and 
the enzymatic activity of the SARS-CoV Mpro.  
2) To identify the dimer interface of the SARS-CoV Mpro. 
3) To understand the regulatory mechanism of the SARS-CoV Mpro by the extra 
domain through structural study. 
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Chapter 3 – Materials and Methods 
 
3.1. Dissection and cloning of the SARS-CoV main protease and its 
fragments 
The full-length SARS-CoV main protease designated as Mpro was identified as 
consisting of 306 residues corresponding to residues 3241–3546 of the SARS 
coronavirus (strain TOR2), on the basis of a sequence comparison with existing 
coronavirus main proteases. Further comparison with the crystallographic structure of 
the transmissible gastroenteritis virus revealed that the SARS-CoV main protease was 
also organized in a three-domain architecture, the first two domains forming a 
chymotrypsin fold (residues 1–196), designated as Mpc, and the third domain 
(197–306) designated as Mph. Molecular cloning was performed on the cDNA 
templates provided by the Genome Institute of Singapore. Because the encoding 
region for the main protease was found to be located over two Genome Institute of 
Singapore constructs (the first 5’-terminal 34 bp were on one construct, and the rest 
were on the other), a two-step procedure was used to obtain the DNA fragment 
encoding Mpro. First, a long forward primer (46 bp) with a sequence of 5’-AGT GGT 
TTT AGG AAA ATG GCA TTC CCG TCA GGC AAA GTT GAA GGG T-3’ and a 
reverse primer, 5’-CGC GCG CTC GAG CTA TTG GAA GGT AAC ACC-3’ were 
designed to replicate the DNA fragment encoding the entire main protease. Second, a 
subsequent PCR reaction with two short primers, 5’-CGC GCG CGG ATC CAG 
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TGG TTT TAG G-3’ (forward) and 5’-GCG CTC GAG CTA TTG GAA GGT AAC 
ACC-3’, was conducted on the above-obtained PCR product to introduce restriction 
enzyme sites. Similarly, the DNA fragment encoding Mpc was replicated by using 
primers 5’-CGC GCG CGG ATC CAG TGG TTT TAG G-3’ (forward) and 5’-GGC 
GGC CTC GAG CTA TGT ACC TGC AG-3’ (reverse), and the DNA fragment 
encoding Mph was replicated with two primers, 5’-CGC GCG CGG ATC CGA CAC 
AAC CAT AAC-3’ (forward) and 5’-CGC GCG CTC GAG CTA TTG GAA GGT 
AAC ACC-3’ (reverse).  
 
3.2. Construction of GST fusion plasmids  
The PCR products encoding the Mpro, Mpc, and Mph were cloned into the 
pGEX-4X-1 vector (Amersham Biosciences), using BamhI/XhoI restriction sites. 
DNA sequencing identified one nucleotide mutation on the constructs resulting in an 
amino acid change (Gly-278 to Asp-278), which was traced back to the original 
Genome Institute of Singapore vector by DNA sequencing. Because this amino acid 
was located on the loop region of the extra helical domain, it most likely did not affect 
the activity of the main protease. No further effort was devoted to change the 
mutation at the N-terminus. In the later experiment, this original G278D mutation, 
had been corrected by site-directed mutagenesis with two primers, 5'-GCT GCA GAA 
TGG TAT GAA TGG TCG TAC TAT CCT TGG TAG C-3' (forward) and 5'-GCT 




3.3. Selection of residues for site-directed mutagenesis 
In an attempt to identify potential extra-domain residues involved in dimerization, 
we decided to conduct alanine site-directed mutagenesis screen on all extra-domain 
residues that have distances equal to or less than 7 Å, with any other residues on the 
opposite protomer of the SARS-CoV Mpro dimeric structure. Thus, we selected one 
deposited crystallographic structure of the SARS-CoV Mpro (PDB code: 1Q2W) as a 
template, and subsequently added hydrogen atoms to the structure, using the graphic 
software yasara (http://www.yasara.org) (Krieger, Vriend 2002). A TCL⁄TK script 
was prepared to calculate the distances between the residues of the extra-domain and 
those on the opposite protomer. Consequently a total of 15 residues were listed, 
including Asn214, Thr280, Leu282, Gly283, S284, Thr285, Ile286, Glu288, Asp289, 
Glu290, Phe291, Arg298, Gln299, Cys300, and Ser301. Since a closer examination of 
the 3D structures, including 1Q2W among others, revealed that both N- and C-termini 
had a large number of contacts with the 15 selected residues, we also generated three 
N- and C-terminal deletion constructs, namely ND (Δ1-5) with N-terminal residues 
1–5 deleted; LHD (Δ293-306) with the last helix (residues 293–306) deleted; CD 
(Δ278-306) with the C-terminal residues 278–306 deleted. Moreover, the examination 
also indicated the extensive contacts between the loop regions (residues 276–290) on 
the two protomers, we also made two loop-replacement constructs, with the loop 
residues 276–290 being replaced by two Gly residues for LR(276–290 ⁄ 2G), and by 
four Gly residues for LR(276–290 ⁄ 4G). 
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All Ala-mutation and deletion constructs were obtained by manipulation of the 
wild-type SARS-CoV Mpro construct obtained previously. By using DNA oligo 
nucleotides as listed in Table 1.3, the single-, triple- and loop-replacement mutations 
were also successfully made by the QuikChange-Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA), and the N-, C-termini deletions were achieved by 
PCR. The DNA fragments obtained were then inserted into the pGEX-4T-1 
GST-fusion expression vector (Amersham Biosciences, GE Healthcare, Little 
Chalfont, United Kingdom) using the BamHI ⁄ XhoI restriction sites. The sequences 
of all constructs were confirmed by DNA automated sequencing.   
 
3.4. Expression and purification of native and mutated SARS-CoV Mpro 
The expression constructs were transformed into the Escherichia coli strain BL21 
to over-express the GST fusion proteins. Briefly, the cells were cultured at 37 °C until 
the absorbance at 600 nm reached 0.7 O.D. Then, 0.5 mM 
isopropyl-1-thio-D-galactopyranoside was added into the cell culture medium to 
induce the foreign protein expression at 20 °C overnight. The cells were then 
centrifuged and sonicated in the cell lysis buffer (50mM NaH2PO4, 150mM NaCl, pH 
7.4, 2mM DTT) to release the GST fusion proteins, which were subsequently purified 
using glutathione-Sepharose (Amersham Biosciences). The in-gel cleavage of the 
fusion proteins was performed at room temperature by incubating the fusion proteins 
attached to the sepharose beads with bovine thrombin. The released recombinant 




Table 1.3  DNA oligos used to generate mutated and deleted SARS-CoV main protease constructs 
Mutant Oligo sequence 
N214A 
Forward 5’-GGC TGT ATG CTG CTG TTA TCG CGG GTG ATA GGT GGT TTC TTA A-3’ 
Reverse 5’-TTA AGA AAC CAC CTA TCA CCC GCG ATA ACA GCA GCA TAC AGC C-3’ 
T280A 
Forward 5’-TGG TAT GAA TGG TCG TGC GAT CCT TGG TAG CAC TA-3’ 
Reverse 5’-TAG TGC TAC CAA GGA TCG CAC GAC CAT TCA TAC CA-3’ 
L282A 
Forward 5’-GGT ATG AAT GGT CGT ACT ATC GCG GGT AGC ACT ATT TTA GAA GAT GA-3’ 
Reverse 5’-TCA TCT TCT AAA ATA GTG CTA CCC GCG ATA GTA CGA CCA TTC ATA CC-3’ 
G283A 
Forward 5’-GAA TGG TCG TAC TAT CCT TGC GAG CAC TAT TTT AGA AGA TGA G-3’ 
Reverse 5’-CTC ATC TTC TAA AAT AGT GCT CGC AAG GAT AGT ACG ACC ATT C-3’ 
S284A 
Forward 5’-GAA TGG TCG TAC TAT CCT TGG TGC GAC TAT TTT AGA AGA TGA GTT TAC-3’ 
Reverse 5’-GTA AAC TCA TCT TCT AAA ATA GTC GCA CCA AGG ATA GTA CGA CCA TTC-3’ 
T285A 
Forward 5’-CGT ACT ATC CTT GGT AGC GCT ATT TTA GAA GAT GAG TTT ACA C-3’ 
Reverse 5’-GTG TAA ACT CAT CTT CTA AAA TAG CGC TAC CAA GGA TAG TAC G-3’ 
I286A 
Forward 5’-CGT ACT ATC CTT GGT AGC ACT GCG TTA GAA GAT GAG TTT ACA CCA TT-3’ 
Reverse 5’-AAT GGT GTA AAC TCA TCT TCT AAC GCA GTG CTA CCA AGG ATA GTA CG-3’ 
E288A 
Forward 5’-CCT TGG TAG CAC TAT TTT AGC AGA TGA GTT TAC ACC ATT TG-3’ 
Reverse 5’-CAA ATG GTG TAA ACT CAT CTG CTA AAA TAG TGC TAC CAA GG-3’ 
D289A 
Forward 5’-CCT TGG TAG CAC TAT TTT AGA AGC GGA GTT TAC ACC ATT TGA TGT TG-3’ 
Reverse 5’-CAA CAT CAA ATG GTG TAA ACT CCG CTT CTA AAA TAG TGC TAC CAA GG-3’ 
E290A 
Forward 5’-GGT AGC ACT ATT TTA GAA GAT GCG TTT ACA CCA TTT GAT GTT GTT-3’ 
Reverse 5’-AAC AAC ATC AAA TGG TGT AAA CGC 
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ATC TTC TAA AAT AGT GCT ACC-3’ 
F291A 
Forward 
5’-GGT AGC ACT ATT TTA GAA GAT GAG 
GCG ACA CCA TTT GAT GTT GTT AGA 
C-3’ 
Reverse 5’-GTC TAA CAA CAT CAA ATG GTG TCG CCT CAT CTT CTA AAA TAG TGC TAC C-3’ 
R298A 
Forward 5’- CAC CAT TTG ATG TTG TTG CGC AAT GCT CTG GTG TTA CCT TCC AAT AG-3’ 
Reverse 5’-CTA TTG GAA GGT AAC ACC AGA GCA TTG CGC AAC AAC ATC AAA TGG TG-3’ 
Q299A 
Forward 5’-CAC CAT TTG ATG TTG TTA GAG CGT GCT CTG GTG TTA CCT TCC AAT AG-3’ 
Reverse 5’-CTA TTG GAA GGT AAC ACC AGA GCA CGC TCT AAC AAC ATC AAA TGG TG-3’ 
C300A 
Forward 5’-CAC CAT TTG ATG TTG TTA GAC AAG CGT CTG GTG TTA CCT TCC AAT AG -3’ 
Reverse 5’-CTA TTG GAA GGT AAC ACC AGA CGC TTG TCT AAC AAC ATC AAA TGG TG-3’ 
S301A 
Forward 5’-GAT GTT GTT AGA CAA TGC GCG GGT GTT ACC TTC CAA TAG-3’ 
Reverse 5’-CTA TTG GAA GGT AAC ACC CGC GCA TTG TCT AAC AAC ATC-3’ 
STI/A 
Forward 5’-GGT CGT ACT ATC CTT GGT GCG GCG GCG TTA GAA GAT GAG TTT ACA C-3’ 
Reverse 5’-GTG TAA ACT CAT CTT CTA ACG CCG CCG CAC CAA GGA TAG TAC GAC C-3’ 
ND (Δ1-5) 
Forward 5’-CGC GCG CGG ATC CAT GGC ATT CCC GTC AGG-3’ 
Reverse 5’-CGC GCG CTC GAG CTA TTG GAA GGT AAC ACC-3’ 
LHD(Δ293-3
06) 
Forward 5’-CGC GCG CGG ATC CAG TGG TTT TAG G-3’ 
Reverse 5’-CGC TCG AGC TAT GTA AAC TCA TCT TC-3’ 
CD(Δ278-306
) 
forward 5’-CGC GCG CGG ATC CAG TGG TTT TAG G-3’ 




forward 5’-CGC GCG CGG ATC CAG TGG TTT TAG G-3’ 
Reverse 
5’-TTG GAA GGT AAC ACC AGA GCA TTG 
TCT AAC AAC ATC AAA TGG TGT AAA 
CTC ATC TTC GCC GCC  ACC ATT CTG 






forward 5’-CGC GCG CGG ATC CAG TGG TTT TAG G-3’ 
Reverse 
5’-TTG GAA GGT AAC ACC AGA GCA TTG 
TCT AAC AAC ATC AAA TGG TGT AAA 
CTC GCC GCC GCC GCC ACC ATT CTG 
CAG CAG CTC TTT C-3’ 
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AKTA FPLC machine (Amersham Biosciences) on a gel filtration column (HiLoad 
16 ⁄ 60 Superdex 200), equilibrated and eluted with a buffer at pH 7.4, and containing 
50 mM NaH2PO4, 150 mM NaCl and 28.8 mM β-mercaptoethanol. The eluted peak 
corresponding to the Mpro or its mutants was collected and buffer-exchanged to a pH 
7.0 buffer, containing 10 mM NaH2PO4, 0.01% NaN3, and 5 mM dithiothreitol (DTT) 
for storage, using Amicon Ultra-15 centrifugal filter devices (5 kDa cutoff, Millipore, 
Billerica, MA, United States). The molecular weights of the recombinant proteins 
were measured using a matrix-assisted, time-of-flight mass spectrometer 
(Voyager-DE™ STR Biospectrometry™ workstation).  
For the heteronuclear NMR experiments and three dimensional NMR 
experiments, the proteins were prepared in 15N-labeled or 13C/15N-labeled forms, 
using a similar expression protocol, except for the E. coli cells, which were grown in 
the M9 media, with an addition of (15NH4)2SO4 for 15N labeling, or/and 13C-label 
glucose for 13C labeling, instead of the LB media. 
For the X-ray crystallography experiments, the buffer system changed from the 
phosphate buffer system to the Tris-HCl buffer system, in order to avoid the growth 
of phosphate crystals. After being purified by gel filtration, the proteins were 
collected and buffer-exchanged to the buffer at pH 7.5, and containing 20 mM 
Tris-HCl, 0.01% NaN3, and 28.8 mM b-mercaptoethanol through dialysis. After 
dialysis, the proteins were further purified by an AKTA FPLC machine (Amersham 
Biosciences), on an ion exchange column (Mono_Q_HR_5/5) equilibrated with a 
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buffer at pH 7.5, and containing 20 mM Tris-HCl, 0.01% NaN3, and 28.8 mM 
b-mercaptoethanol, and eluted with a buffer at pH 7.5, and containing 20 mM 
Tris-HCl, 1 M NaCl, 0.01% NaN3, and 28.8 mM b-mercaptoethanol in gradient. The 
eluted peak corresponding to the Mpro or its mutants was collected and 
buffer-exchanged to a buffer at pH 7.5, and containing 20 mM Tris-HCl, 0.01% NaN3, 
and 5 mM dithiothreitol (DTT) for storage, using Amicon Ultra-15 centrifugal filter 
devices (5 kDa cutoff, Millipore, Billerica, MA, United States). 
 
3.5 Construction of SARS-CoV Mpro Arg298Ala mutant with authorized 
N-termini  
Due to the fact that the additional N-terminal residues (GS) inherited from the 
expression vector can significantly affect dimerization, enzymatic activity, and the 
crystallization ability of the SARS-CoV Mpro, we decided to remove the GS-tag on 
the N-termini of the SARS-COV Mpro, by changing the endopeptidase from the 
thrombin to the factor Xa. The new construct of the SARS-CoV Mpro Arg298A 
mutant with the factor Xa cleavage site was obtained by manipulation of the 
SARS-CoV Mpro Arg298A with the thrombin cleavage site. By using two primers, 5'- 
GGC GAC CAT CCT CCA AAA TCG GAT CTG ATC GAA GGT CGT AGT GGT 
TTT AGG AAA ATG GCA TTC CCG -3'(forward) and 5'- CGG GAA TGC CAT TTT 
CCT AAA ACC ACT ACG ACC TTC GAT CAG ATC CGA TTT TGG AGG ATG 
GTC GCC-3'(reverse), the thrombin cleavage region CTG GTT CCG CGT GGA TCC 
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(LVPR|GS) on the original plasmid was converted to the factor Xa region ATC GAA 
GGT CGT (IEGR|) through the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, United States). The sequence of the new construct was 
confirmed by DNA automated sequencing. 
 
3.6 Expression and purification of SARS-CoV Mpro Arg298Ala mutant 
with authorized N-termini 
The new construct of the SARS-CoV main protease Arg298Ala mutant was 
transformed into the E.Coli strain BL21 (DE3), and induced by 0.4mM IPTG at 22 
degree overnight, followed by a purifying step with Glutathione Sepharose. The in-gel 
cleavage of the fusion proteins was performed at 4 oC, by incubating the fusion 
proteins attached to the sepharose beads with the 40 units of factor Xa for seven days. 
The released recombinant proteins were further purified by gel filtration and ion 
exchange. The final purified protease was stored at 10mg/ml in a pH 7.5 buffer, with 
10 mM Tris-HCl, 0.01% NaN3, and 5 mm dithiothreitol (DTT) for the crystallization 
screen.  
 
3.7. Substrate design and HPLC-based enzymatic activity measurement 
A 14-mer peptide S1 with amino acid sequences of ITSAVLQ|SGFRKMA was 
designed to mimic the N-terminal autocleavage sites of the SARS-CoV main protease, 
and, thus served as the substrate for the SARS-CoV main protease in all 
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measurements reported in the present study. A 7-mer peptide, S2, with a sequence of 
ITSAVLQ, and a 14-mer peptide, S3, with a sequence of SGFRKMAFPSGKVE, 
were designed to mimic the N- and C-terminal products cleaved by the SARS-CoV 
main protease. The peptides were synthesized (Genesis Biotech Inc. Taipei, China) 
and subsequently purified by a reverse-phase HPLC C18 column. Their identities 
were verified by MALDI-TOF mass spectrometry and NMR resonance assignments. 
The enzymatic assay was performed in 50 mM phosphate buffer (pH 7.4) containing 5 
mM dithiothreitol and 150 mM NaCl. Usually, the peptide concentrations ranged 
between 100 to 500 μM, and the protein concentrations ranged from 1 to 30 μM.  
 
3.8. Chemical synthesis of fluorogenic substrate peptides and FRET 
enzymatic activity assay 
The enzymatic activities of the wild-type and mutated SARS-CoV main proteases 
were measured by a fluorescence resonance energy transfer (FRET)-based assay, 
using the fluorogenic substrate peptide. The substrate peptide, with a pair of internally 
quenched fluorescent groups, Dabacyl and Edans, in a sequence of 
Dabcyl-KTSAVLQSGF RKME-Edans, was chemically synthesized (Genesis Biotech 
Inc. Taipei, China), and purified by HPLC on a RP C18 column (Vydac). Briefly, the 
reaction mixture contained 1 μM protease and 3 μM fluorogenic substrate in a buffer 
at pH 7.0, with 5.5 mM NaH2PO4 and 5 mM DTT. The enzyme activity was measured 
by monitoring the increase of the emission fluorescence, at a wavelength of 538 nm 
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with excitation at 355 nm, using a Perkin-Elmer LS-50B luminescence spectrometer. 
For each mutant protease, the activity measurements were carried out at three 
different NaCl concentrations: 0 mM, 100 mM, and 1050 mM, while under each 
condition four independent measurements were performed. 
 
3.9. Circular Dichroism (CD) Spectroscopy 
Circular dichroism (CD) experiments were performed on a Jasco J-810 
spectropolarimeter equipped with a thermal controller. The samples were prepared in 
a 20 mM phosphate buffer at pH 6.8, with protein concentrations ranging from 
20–100 μM. Far-UV CD spectra from 190–260 nm were collected, using a 1-mm path 
length cuvette with a 0.1nm spectral resolution. Five independent scans were 
averaged for each sample. Thermal unfolding with a temperature range of 20–95 °C 
was monitored at 222 nm at several protein concentrations. 
 
3.10. Dynamic light scattering and size-exclusion FPLC analysis 
For dynamic light-scattering analysis, the measurements were performed at 25 °C 
on a DynaPro-MS/X instrument (Protein Solutions Inc.). The protein samples were 
dissolved in a phosphate buffer at pH 7.4, with the presence of 5 mM dithiothreitol to 
prevent the possible formation of an intermolecular disulfide bridge. Molecular mass 
values were calculated by the Protein Dynamics analysis software, using the standard 
conditions molecular weight curve, which is the mean of five readings. For the 
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size-exclusion FPLC analysis, protein samples with a wide spectrum of 
concentrations from 1–600μM were loaded to a Hiload 16/60 Superdex 200 column 
(Amersham Biosciences), and then eluted with a phosphate buffer at pH 7.4, with a 
flow rate of 1 ml/min. The column calibration was conducted with a low molecular 
weight protein kit (Amersham Biosciences) with four proteins: ribonuclease A (15.6 
kDa), chymotrypsinogen A (22.8 kDa), ovalbumin (48.9 kDa), and albumin (65.4 
kDa). 
 
3.11. NMR experiments and structure generation 
The NMR samples of the 15N-labeled Mpro and its mutants were prepared by 
exchanging the buffer of the proteins with a 20 mM sodium phosphate buffer (pH 6.8). 
Samples of the synthetic peptides S1, S2, and S3 were prepared by dissolving the 
lyophilized peptides in 400 μl of an aqueous buffer, containing 20 mM sodium 
phosphate (pH 6.8). The deuterium lock signal for the NMR spectrometers was 
provided by the addition of 40 μl of D2O.  
For the NMR line-broadening study, two identical substrates with a concentration 
of 0.4 mM were prepared in the 20 mM phosphate buffer at pH 6.8, for each NMR 
experiment. For the titration with Mpro, the concentrated protein was added to the  
S1 peptide sample to reach a molar ratio of 1:40 (protein: peptide), and this sample 
was kept at room temperature overnight in order to have the S1 peptide completely 
cleaved by the Mpro, as monitored by HPLC. Titration was conducted later by adding 
 65 
 
more Mpro into the samples. The contribution of the added Mpro, Mpc, and Mph to 
the NMR spectra was removed by subtracting the spectra of the proteins from the 
spectra of the peptides in the presence of the proteins. For the transferred NOE 
experiment, the S1 peptide (1.5 mM) was mixed with the Mpro overnight at a molar 
ratio of 20:1 (peptide: protease).  
All NMR experiments, including two-dimensional NOESY (JEENER J 1979), 
TOCSY (Bax 1985), and 1H-15N HSQC (Sattler M. 1999), were collected on a Bruker 
Avance 500 MHz NMR spectrometer, equipped with an actively shielded cryoprobe, 
and pulse field gradient units at 25 °C. A mixing time of 250 ms was used for 
NOESY, and 65 ms for the TOCSY experiments. Spectral processing and analysis 
were carried out using the XwinNMR (Bruker) and NMRview software (Johnson 
2004). Sequence-specific assignments for the synthetic peptides were achieved 
through identification of spin systems in the TOCSY spectra, combined with 
sequential NOE connectivities in the NOESY spectra (Wagner, Wuthrich 
1982;wuthrich K 1986).  
For structure modeling, NOE connectivities were collected from the NOESY 
spectra of the S1 peptide, and subsequently converted into a uniform upper-bound 
interproton distance of 5.0 Å. The sum of the van der Waals radii of 1.8 Å was set to 
be the lower distance bound. The solution structure of S1 peptide was calculated on a 
Linux-based PC station, by using the simulated annealing protocol in the CNS 
program (Brunger et al. 1998). The structures were analyzed by using YASARA 
(Krieger, Vriend 2002), MolMol (Koradi et al. 1996), and Pymol graphic software 
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(Warren L.DeLano, . 2007). 
 
3.12. Crystallization of SARS-CoV Mpro mutants 
Ten SARS-CoV Mpro enzymatic activity-deficiency mutants, including six single 
mutants Asn214Ala, Glu288Ala, Asp289Ala, Glu290Ala, Arg298Ala, and Gln299Ala, 
one triple mutant NRQ (Asn214-Arg298-Gln299/Ala), two truncated mutants 
ND(ᇞ1-5) , LHD(ᇞ293-306), and one multiple mutant MA (ᇞ1-5, Asn214-Glu288- 
Asp289-Glu290-Arg298-Gln299/Ala), together with four SARS-CoV Mpro 
enzymatic activity-enhanced mutants, including three single mutants Ser284Ala, 
Thr285Ala, and Ile286Ala, and one triple mutant STI (Ser284-Thr285-Ile286/Ala), 
were selected for the protein structure determination by X-ray crystallography. The 
SARS-CoV Mpro R298A mutant with authorized N-termini (R298AN) was also 
prepared for crystallization. 
After a careful analysis of all the published crystallization conditions for the 
SARS-CoV Mpro from PDB, a new PEG screen assay, including various percentages 
of PEG 200, 400, 550(m), 1k, 1.5k, 2k(m), 4k, 5k, 6k, 8k, 10k, and 20k, had been set 
up with 0.1 M Mes at pH 6.0. By using this assay, six out of 15 SARS-CoV Mpro 
mutants can form crystals. Two of them, STI/A and N214A mutants, formed 3D 
crystals. The remaining four mutants (R298A, R298AN, Q299A, and NRQ/A) formed 
2D crystals. After optimization and post-crystallization treatment, three SARS-CoV 
Mpro mutant crystals have been grown into high quality crystals, including 1) one 
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activity-enhanced triple mutant STI (Ser284-Thr285-Ile286/Ala), and 2) two 
activity-deficiency mutants R298A and R298AN (Table 2.3). 
 
3.13 Data collection, structure solution, refinement, and analysis 
The crystals had first been tested on an R-axis IV++ image plate detector 
mounted on a RU-H3RHB rotating anode generator (Rigaku Corp., Tokyo, Japan), at 
50kV and 100mA. The full sets of X-ray diffraction images for the SARS Mpro 
STI/A, R298A and R298AN mutants were collected at the beam line X29c, National 
Synchrotron Light Source, Brookhaven National Laboratory, using a Q315 CCD 
detector (Area Detector Systems Corp., Poway, CA, United States), at wavelength 
1.0810Å. All the crystals were protected by the cryoprotectant (Table 3). The data 
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3.13.1 Phase determination, structure determination, and refinement for 
SARS-CoV Mpro STI/A mutant 
The phase for the SARS-CoV Mpro STI/A mutants was determined by molecular 
replacement. The initiate models for the SARS-CoV Mpro STI/A was generated by 
the software phaser, using one SARS-CoV Mpro protomer structure (PDB: 1UJ1, 
residue 3-300), as a search model against the diffraction datasets. The amino acid 
mutations (S284, T285 and I286 mutate to A) were observed in the electron density, 
and were replaced by Ala in COOT (Emsley, Cowtan 2004). This model was 
completed by manual fitting in COOT and the several rounds of structure refinements 
were done in CNS. Water molecules were added into the model by the CNS 
water_pick model. During model building and refinement, 7% of the data was 
reserved for cross validation, so as to monitor the refinement process. 
3.13.2 Phase determination, structure determination, and refinement for 
SARS-CoV Mpro R298A and R298AN mutants 
The attempt to solve the structure of the SARS-CoV Mpro R298AN, using the 
wild-type SARS-CoV Mpro structure (PDB entry 1UJ1) as a search model, after 
removing the protomer B and water molecules by molecular replacement, was 
unsuccessful. The entire domain III could not be located into the electron density on 
the 2fofc map. Since the structure of domain III is very stable, even under 1M 
guanidinium chloride, it is unlikely that a C-terminal point mutation R298A can 
disrupt the entire domain III structure. Because a long loop (172-199) links the 
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catalytic domains and domain III, the orientation among domains may be affected by 
this mutation. Two pdb files were generated based on the wild-type SARS-CoV Mpro 
structure (1UJ1). One pdb file contains the catalytic domain (from residues 15–172), 
while another pdb file contains domain III (from residues 207–300). The initial model 
of the SARS-CoV Mpro R298AN mutant containing ~252 residues was generated by 
the program Phaser 1.3, using the two pdb files as separate ensembles, through the 
molecular replacement method. This model was completed by manual fitting, using 
the program COOT, and refined using the program CNS 1.2 for several rounds. The 
final model contains all 306 residues of SARS-CoV Mpro R298AN mutant. There are 
457 water molecules included in the model by using the water_pick module in CNS 
1.2. During model building and refinement, 5.4% of the data were reserved for cross 
validation, so as to monitor the refinement process. The SARS-CoV Mpro R298A 
mutant structure was solved using the R298AN as search model. The N-terminal Gly 
and Ser residues were manually fitted in COOT.  
 
3.14 Analytical ultracentrifuge  
Sedimentation velocity experiments were done using a Beckman Coulter XL-I 
analytical ultracentrifuge. Briefly, the R298AN protease was in dialysis against the 
buffer (10 mM Tris-HCl (pH 7.5), 14.4 mM β-mercaptoethanol (β-ME)), and 
subsequently concentrated to 3 mg/ml, for preparing samples at various protease 
concentrations. For the sedimentation velocity experiment, sample (400 μl) and 
reference (440 μl) solutions were loaded into standard, double-sector centerpieces, 
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and mounted in a Beckman An-50 Ti rotor. Experiments were conducted at 20 oC with 
a rotor speed of 42,000 rpm. Absorbance of the sample at 280 nm, or 285 nm or 290 
nm was monitored in a continuous mode without delay, and with a step size of 0.003 
cm, without averaging.  Multiple scans at different time points were fitted into a 
continuous size distribution, using SEDFIT 9.4c. A partial specific volume of 0.7311 
cm3/g was calculated from the amino acid sequence of the R298A protease, and the 















Chapter 4 - Dissection Study on the Severe Acute 
Respiratory Syndrome coronavirus main Protease Reveals 
the Critical Role of the Extra Domain in the Dimerization of 
the Enzyme 





4.1.1. Cloning and Expression of Mpro, Mpc, and Mph 
We have cloned and expressed the entire SARS-CoV main protease (Mpro) and 
its two dissected parts (Mpc and Mph) as GST fusion proteins in E. coli BL21 cells. 
The purified Mpro, Mpc, and Mph were successfully isolated from GST through 
in-gel thrombin cleavage (Figure 1.4). The molecular weights of the purified proteins 
were characterized by MALDI-TOF MS. As seen in Table 1.4, except for the entire 
enzyme (which could not be ionized under several MS conditions probably due to 
very high molecular weight and the dimerization), two dissected parts have molecular 
weights very close to predicted ones, indicating that no unspecific cleavage happened 
during the thrombin cleavage.  
The enzymatic activities of the Mpro, Mpc, and Mph were measured by using a 
14-mer S1 peptide as a substrate. With a protein concentration of 20 μM, the 




Figure 1.4 - Expression and purification of the SARS-CoV main protease 
(Mpro) and its two dissected fragments Mpc and Mph  
 
(a) Samples of the full-length main protease on a 12% SDS-PAGE gel. Lane 1, 
total cell extract with a 0.5 mM isopropyl-1-thio--D-galactopyranoside induction 
at 20 °C overnight. Lane 2, supernatant of the cell lysate by centrifugation (18k 
rpm 30mins). Lane 3, mixture of the in-gel cleavage of the GST-Mpro fusion 
protein by thrombin at room temperature for 4 h. Lane 4, purified main protease. 
Lane 5, protein molecular weight markers.  
 
(b) Samples of the dissected fragment Mpc protein on a 12% SDS-PAGE gel. 
Lane 1, total cell extract with a 0.5 mM isopropyl-1-thio--D-galactopyranoside 
induction at 20 °C overnight. Lane 2, supernatant of the cell lysate by 
centrifugation (18k rpm 30mins). Lane 3, beads after the in-gel cleavage of the 
GST-Mpc by thrombin at room temperature for 4 h. Lane 4, supernatant after the 
in-gel cleavage of the GST-Mpc by thrombin at room temperature for 4 h. Lane 
5, purified Mpc protein. Lane 6: protein molecular weight markers.  
 
(c) Samples of the dissected fragment Mph protein on a 15% SDS-PAGE gel. 
Lane 1, total cell extract with a 0.5 mM isopropyl-1-thio--D-galactopyranoside 
induction at 20 °C overnight. Lane 2, supernatant of the cell lysate by 
centrifugation (18k rpm 30mins). Lane 3, mixture after the in-gel cleavage of the 
GST-Mph by thrombin at room temperature for 3 days. Lane 4, purified Mpc 




Table 1.4 - Molecular weights (Mr) of the entire SARS-CoV main protease 
(Mpro) and two dissected parts, Mpc and Mph, as measured by MALDI-TOF 
MS and dynamic light scattering (DLS)  
 Predicted Mr  Measured by MS Measured by DLS 
Mpro  34047.88  ND  63.0 ± 1.5  
Mpc  21732.84  21755.81  22.0 ± 1.0  





Figure 2.4 - Catalytic activities of the SARS-CoV main protease on the substrate 
peptide S1 as monitored by HPLC chromatography on an RP-18 column (Vydac) 
Cleavage reactions were carried out at room temperature in 50 mM phosphate buffer 
(pH 7.2) with 5 mM dithiothreitol, and 150 mM NaCl, containing 0.3 mM S1 peptide, 
and 20 μM recombinant proteins. At different points of time, a volume of 80 μl of 
reaction mixture was removed and mixed with 40 μl of 10% trifluoroacetic acid to 
stop the reaction. Subsequently, the acidified mixture was analyzed by HPLC. (a) 
HPLC profile of the cleavage reaction by Mpro. Black—0 min, green—10 min, 
red—1 h. (b) HPLC profile of the cleavage reaction by Mpc. Black—0 min. 
green—20 h; red, 80 h. 
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As shown in Figure 2a.4, only 10 minutes after initiating the reaction by mixing the 
Mpro with peptide S1, about 15% of the peptides were cut into two short peptides. 
After 1 h, The S1 peptide was completely cleaved. On the other hand, as shown in 
Figure 2b.4, although the dissected part Mpc contained the complete catalytic 
machinery homologous to the picornavirus 3C protease, it showed a very weak 
catalytic activity on the S1 peptide. After 20 h of the initiation, only 20% peptide was 
cleaved, and 35% peptide was cleaved after 80 h. The cleavage experiment failed to 
detect any catalytic activity of the Mph on the peptide S1. 
 
4.1.2. Structural Characterization by CD and NMR Spectroscopy 
Far-UV CD spectroscopy was used to measure the secondary structures of the 
Mpro, Mpc, and Mph at a 30 μM protein concentration. As shown in Figure 3a.4, all 
three proteins had well formed secondary structures. The CD spectrum of the 
full-length main protease indicated that it assumed a α/β structure. On the other hand, 
the Mpc had a spectrum typical of a β-sheet structure with a negative peak at 221 nm 
and a positive peak at 199 nm, whereas the Mph had a spectrum characteristic of a 
α-helical structure with dual negative peaks at 221 and 209 nm. The thermal stability 
of all the three proteins was assessed by monitoring the continuous changes in the 
ellipticity at 222 nm in the temperature range 20–93 °C. The results shown in Figure 
3b.5 indicated that both the Mpro and Mpc started to precipitate at 48 and 56 °C, 
respectively. For the extra domain Mph, the conformation underwent an unfolding, 
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but no precipitation was observed. Interestingly, even at 93 °C the structure of the 
Mph was not completely denatured, and its CD spectrum appeared to resemble that of 
a β-sheet protein. The structural properties of the three proteins were further 
investigated by the use of NMR 1H-15N HSQC spectroscopy, which is very sensitive 
to both the secondary structure and tertiary packing. For the full-length main protease, 
the attempt to collect a HSQC spectrum failed, probably due to the relaxation 
properties, or/and aggregation commonly observed for large proteins. However, its 
one-dimensional proton NMR spectrum presented in Figure 4a.4 indicated that the 
Mpro would be structured with a tightly packed tertiary structure, as evidenced from 
the several very up-field NMR resonance peaks at 0.25 and 0.76 ppm, although these 
NMR lines were very broad, again mostly due to a very large molecular mass (68 kDa 
after dimerization), or/and further aggregation. However, it is very hard to exclude the 
possibility that the entire main protease (Mpro) might have some properties of the 
molten globule in solution, although it was shown that the SARS-CoV Mpro adopted 
a well-packed structure in the crystal. Strikingly, well-dispersed HSQC spectra were 
obtained for the Mpc and Mph (Figures 4b.4 and 4c.4), conclusively indicating that 
two isolated fragments had not only well formed secondary structures, as shown by 
CD spectra, but were also well packed tertiary structures. As shown in Figure 4b.4, 
many downfield resonance peaks (8.5 ppm) were observed, indicating the Mpc 
adopted a β-sheet structure, consistent with the CD observation. On the other hand, as 
seen in Figure 4c.4, only a small portion of downfield resonance peaks (8.5 ppm) was 




Figure 3.4 - CD characterization of the structure and stability of the Mpro, 
Mpc, and Mph  
(a) Far-UV CD spectra of three recombinant proteins at a 50 μM concentration in a 
20 mM phosphate buffer (pH 6.8) at 20 °C. Black—full-length SARS-COV main 
protease, Mpro, purple—Mpc, and cyan—Mph.  
(b) Thermal unfolding followed at 222 nm, with a temperature range from 20 to 




Figure 4.4 - NMR characterizations of the 15N isotope-labeled Mpro, Mpc, 
and Mph 
(a) A one-dimensional NMR spectrum of the full-length SARS main protease 
at 25 °C in a 20 mM phosphate buffer (pH 6.8).  
(b) A two-dimensional 1H-15N HSQC spectrum of the Mpc protein at 25 °C in 
a 20 mM phosphate buffer (pH 6.8).  
(c) A two-dimensional 1H-15N HSQC spectrum of the Mph protein at 25 °C in 











4.1.3. Dimerization of the Extra Helical Domain Mph 
As seen in Table 1.5, the molecular weights of the Mpc and Mph proteins measured 
by MALDI-TOF MS were very close to those predicted from their amino acid 
sequences, indicating that both dissected domains had no unwanted truncation. 
Interestingly, when measured by dynamic light scattering, the molecular mass of the 
entire main protease was estimated to be around 63.0 kDa, indicating that 
dimerization of the entire enzyme had occurred to some extent. On the other hand, the 
molecular masses of the dissected Mpc and Mph were estimated to be around 22.0 
and 21.0 kDa, respectively. The results clearly indicated that the dissected catalytic 
domain Mproc existed as a monomer, whereas the dissected helical domain Mproh 
existed as a dimer. Because the dynamic light-scattering measurement requires a 
narrow range of the protein concentration to achieve good results, we therefore further 
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followed the concentration dependence of dimerization by using FPLC 
chromatography (superdex 200). As showed in Figure 5.5, only the full-length Mpro 
showed a concentration-dependent dimerization, and it existed mostly as a monomer 
at a protein concentration less than 0.2 mg/ml, consistent with the recent report (Fan 
et al. 2004). It is also worthwhile to note that the catalytic domain remained as a 
monomer even at a very high protein concentration (14.8 mg/ml). Very interestingly, 
the isolated extra domain Mph existed as a dimer even at a very low protein 
concentration (0.12 mg/ml), and showed no concentration dependence. The 
observation that the chymotrypsin fold Mpc existed as a monomer at a very high 












Figure 5.4 - Concentration-dependent dimerization of the Mpro, Mpc, and 
Mph, as monitored by FPLC chromatography 
(a) FPLC profiles for the Mpro. Blue: Mpro with a protein concentration of 9.2 
mg/ml, and elution volume of 81.92 ml. Gray—Mpro with a protein concentration 
of 0.98 mg/ml and elution volume of 84.12 ml, pink—Mpro with a protein 
concentration of 0.8 mg/ml and elution volume of 84.92 ml.  
(b) FPLC profiles for the Mpc. Blue—Mpc with a protein concentration of 14.88 
mg/ml and elution volume of 93.5 ml, red—Mpc with a protein concentration of 
1.28 mg/ml and elution volume of 94.07 ml, brown—Mpc with a protein 
concentration of 0.48 mg/ml and elution volume of 93.97 ml, pink—Mpc with a 
protein concentration of 0.1 mg/ml and elution volume of 94.22 ml. 
(c) FPLC profiles for the Mph. Pink—Mph with a protein concentration of 2.63 
mg/ml and elution volume of 96.07ml, gray—Mph with a protein concentration of 
0.56 mg/ml and elution volume of 95.73ml, blue—Mph with a protein 
concentration of 0.12 mg/ml and elution volume of 96.24 ml. 
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low concentration, strongly implies that the extra domain contributes significantly to 
the dimerization of the SARS main protease. 
4.1.4. Binding Interactions of Mpro, Mpc, and Mph with Substrate 
Peptides 
The NMR differential line-broadening and transferred NOE experiments are 
powerful probes for characterizing protein-peptide interactions in the fast exchange 
regime on the NMR time scale. Figure 7.4 presents the aliphatic and aromatic regions 
of the one-dimensional NMR spectra of the 14-mer S1 peptide, in the absence and 
presence of Mpro, Mpc, and Mph. Figure 8a.4 showed the spectral region with NMR 
resonance peaks from the side chains of the residues Ile-1, Val-5, and Leu-6, in the 
absence and presence of the full-length main protease at different ratios. It can be seen 
that, with the addition of the full-length main protease at a ratio of 1:40 (protein: S1 
peptide), most resonance peaks started to become broadened. This broadening process 
was demonstrated by the peaks resulting from the methyl group of the residue Leu-6, 
which was well separated from the other peaks (Figure 8a.4). The line broadening 
became more severe when more main protease was added to reach a ratio of 20:1 
(Figure 7a.4). This observation indicated that the binding interactions occurred 
between the main protease and the side chains of Val-5 and Leu-6 in the fast 
exchange regime. Interestingly, similar line broadening of the aromatic resonance 
peaks from the residue Phe-10 were also observed (Figure 7b.4), indicating that both 
the N-terminal half represented by residues Val-5 and Leu-6, and the C-terminal half 
carrying residue Phe-10, interacted with the full-length main protease, even after the 
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cleavage of the S1 peptide at Gln-6—Ser-7 bond was completed. Similar experiments 
were carried out with Mpc and Mph, and the results are shown in Figure 7c-f.4. 
Surprisingly, additions of Mpc and Mph resulted in no significant line broadening of 
the NMR resonances, indicating that S1 peptide had no detectable binding interaction 
with either dissected fragments. This conclusion was further confirmed by HSQC 
titrations of the 15N-labeled Mpc and Mph with S1 peptide. No significant HSQC 
peak shift was observed for both Mpc and Mph, even in the presence of S1 peptide at 
up to a 20 excess. To confirm the interaction between the main protease and the two 
cleaved fragments of the S1 peptide, the NMR differential line-broadening 
experiments were further conducted on 7-mer S2 and 14-mer S3 peptides. As seen in 
Figure 6a.4, line broadening and peak shifts were observed when the main protease 
was added to the 7-mer N-terminal half of the cleaved fragments. As far as the 14-mer 
C-terminal half was concerned, very extraordinarily, the addition of the Mpro even 
induced the line broadening and peak shifts for the residue Val-13 of the S3 peptide. 
These results suggest that the amino acids C-terminal at the cleavage site also have 
extensive interactions with the main protease. 
 
5.1.5. Preferred Conformations of S1 Peptide 
The structural properties of the S1 peptide in the absence and presence of the 
full-length main protease were further addressed by two dimensional NMR 
experiments. As seen in Figure 8a.4, in the free state, the aromatic ring of the residue  
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Figure 6.4 - Binding interactions of the S2 and S3 peptides with Mpro, as 
followed by differential NMR line-broadening: 
All spectra were collected at 25 °C in a 20 mM phosphate buffer (pH 6.8), in the 
absence or presence of the Mpro at different molar ratios.  
(a) NMR spectrum of the S2 peptide over 0.76–0.99 pm. The well separated 
NMR peaks from the methyl groups of the residue Leu-6 were labeled. NMR 
spectra of S3 peptide over two spectral regions were presented. They are, the 
0.87–0.97 ppm region, resulting from resonance peaks from the methyl groups 
of the residues Val-13 
(b), and the 7.20–7.42 ppm region, resulting from the overlapped aromatic 
protons of Phe-3 and Phe-8  
(c). Spectra in black: in the absence of Mpro, green—in the presence of Mpro at 
a molar ratio of 1:40 (protein/peptide), red–in the presence of Mpro at a molar 
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Figure 7.4 - Binding interactions of the substrate peptide S1 with Mpro, Mpc, and 
Mph, as probed by NMR differential line broadening  
All spectra were collected at 25 °C in a 20 mM phosphate buffer (pH 6.8) in the absence 
or presence of recombinant proteins at different molar ratios. Two NMR spectral regions 
of the S1 peptide were presented: the 0.77–0.99 ppm region, resulting from resonance 
peaks of the aliphatic side chains of the residues Ile-1, Val-5, and Leu-6, and the 7.15–7.40 
ppm region, resulting from the aromatic protons of the residue Phe-10. (a) and (b), two 
spectral regions in the presence of Mpro at different ratios. Black—in the absence of 
Mpro, green–in the presence of Mpro at a molar ratio of 1:40 (protein/peptide), red–in the 
presence of Mpro protein at a molar ratio of 1:20 (protein/peptide). (c) and (d), two 
spectra regions in the presence of the Mproc. Black—in the absence of Mproc, red—in 
the presence of Mproc at a molar ratio of 1:20 (protein/peptide). (e) and (f), two spectral 
regions in the presence of the Mproh. Black—in the absence of Mproc, red—in the 
presence of Mproh at a molar ratio of 1:20 (protein/peptide). 
 87 
 
Phe-10 had extensive long-range contacts with the side chains of the residues Val-5 
and Leu-6. These NOE connectivities summarized in Figure 8b.5 indicate the 
formation of a β-turn conformation over the residues Val-5 to Phe-10. Interestingly, 
even after the S1 peptide was cleaved into two fragments by the main protease at 
Gln-7—Ser-8 bond, similar transferred NOE patterns could still be observed, although 
most NOE resonances were too broadened to be discriminated from the noise. For 
example, there were still NOEs between the HG protons of the residue Gln-7, and the 
HD protons of the residue Phe-10, and between HD/HE/HZ protons of the residue 
Phe-10, and HG/HD protons of the residue Leu-6. This observation strongly suggests 
that although S1 peptide was cleaved into two fragments at the Gln-7–Ser-8 bond, the 
two parts were still bound to the main protease and the spatial relationship between 
two fragments might still remain similar to that adopted by the uncleaved S1 peptide 
in the free state. 
The NOE connectivities were used to model the preferred conformation of the S1 
peptide. Figure 8c.5 presents the eight lowest energy structures of the S1 peptide 
superimposed over residues Val-5 to Phe-10. It is interesting to note that the β-turn 
region is well defined, whereas the rest of the molecule, such as the N and C-terminal 
tails, is flexible. It appears that this β-turn conformation is stabilized by the 
interactions between the aromatic ring of the residue Phe-10, and the hydrophobic 
side chains of the residues Val-5 and Leu-6, as previously observed for small peptide 
fragments and partially folded intermediates. The relatively flexible β-turn 
conformation observed in the free state should allow the local conformational 
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Figure 8.4 - Solution conformation of the S1 substrate peptide  
(a) The aromatic-aliphatic regions of the NOESY spectra of the S1 peptide in a 20 
mM phosphate buffer (pH 6.8) in the absence of the Mpro (black) and in the 
presence of the 1/20 Mpro (red). The key NOE connectivities are labeled, to 
indicate the presence of a -turn conformation.  
(b) The amino acid sequence of the S1 peptide with key NOE connectivities 
defining the -turn over the residues Val-5 to Phe-10.  




The central role of the SARS-CoV main protease in the life cycle of the virus 
ranks this enzyme as a top target for the design of anti-SARS drugs. Compared with 
picornavirus 3C proteases, the SARS main protease, like the other coronavirus main 
proteases, gained an extra C-terminal helical domain during the evolution. Previously, 
no clue has been available regarding the functional role of this extra domain, and it 
was extensively believed that the coronavirus main proteases and picornavirus 3C 
proteases shared similar enzymatic mechanisms and substrate specificity. On the other 
hand, several previous attempts have utilized the fragment deletion approach (Anand 
et al. 2002;Lu, Denison 1997;Ziebuhr et al. 1997;Ng, Liu 2000) to assess the role of 
the extra domain, and have demonstrated that the extra domain was indispensable for 
the activity of the coronavirus main proteases. However, because no structural 
property of the truncated fragments was acquired, the possibility still existed that the 
loss of activity might be simply the consequence of the misfolding of truncated forms.  
In the present study, we first demonstrated that the significant activity loss of the 
catalytic fold Mpc, a structural homologue of the picornavirus 3C protease, was not 
due to misfolding. Most importantly, we have discovered that the extra helical domain 
contributed to the dimerization of the enzyme. Considering the observations that only 
the dimer form is the active form of the main proteases (Anand et al. 2002;Yang et al. 
2003;Fan et al. 2004;Ng, Liu 2000), we therefore propose that one key role of the 
extra domain unique to the SARS-CoV main proteases is to regulate the activity and 
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specificity of the main proteases, by controlling the association-dissociation 
equilibrium of the enzyme. Our results also strongly indicate that the catalytic 
mechanism of the coronavirus main proteases is totally different from that of the 
picornavirus 3C proteases, which only require the presence of the chymotrypsin fold. 
The observation that the isolated helical domain was fully folded implies that this 
extra domain may further interact with other proteins/biomacromolecules to link the 
activity and specificity of the main proteases to other signaling networks, as was 
previously proposed for other viral proteases. Consequently, our current study defines 
the dimer interface on the extra domain as a new target for the design of specific 
inhibitors for the SARS-CoV main protease. In the present study, other features 
unique to the SARS-CoV main protease were also illustrated. Our results clearly 
indicate that only the entire enzyme is capable of interacting with the substrate 
peptide S1. Furthermore, to our surprise, unlike other proteases such as hepatitis C 
virus N3 protease, which only binds to the N-terminal part after the substrate cleavage, 
the SARS-CoV main protease showed binding interactions with both the N- and 
C-terminal parts of the cleaved substrate peptide S1. These observations indicate that 
the interaction interface between the SARS-CoV main protease and its in vivo 
substrates might be very large, and the enzymatic activity and specificity are under 
regulation by many factors.  
It is also worth noting that the substrate peptide S1 adopts a preferred β-turn 
conformation over residue Val-5 to Phe-10, that might remain similar after being 
bound to the enzyme, as was implied by the transferred NOE study. Indeed, the 
 92 
 
conformational similarity between the free state and the bound state was previously 
observed for a thrombin inhibitor. These results are particularly enlightening in light 
of the recent CD study on the conformations of the 11 substrate peptides for the 
SARS-CoV main protease, which implied that substrates with more turn-like 
conformation tended to react faster with the enzyme. These results together offer a 
novel possibility for the design of active-site inhibitors that differ from the current 
design by which the inhibitors were only derived from the N-terminal half of the 
cleaved substrate. Certainly it is worth attempting to design active site inhibitors, 
based on the β-turn conformation obtained in our study (Figure 8c.4).  
Our results not only bear fundamental implications, but they offer valuable clues 
for the design of inhibitors for the SARS-CoV main protease. Considering the pivotal 
role of the helical domain in controlling the dimerization of the enzyme, it is logically 
anticipated that the disruption of the dimer interface could be a promising strategy to 
develop novel inhibitors targeting at main proteases. For example, phage-display or a 
natural product library could be used to screen ligands binding to the dimer interface 
on the extra domain. Consequently, a promising strategy might be established in 
which two separate inhibitors, one binding to the active site, and another disrupting 
the dimer interface on the extra domain, are linked together to create a bi-functional 
inhibitor with significantly enhanced binding affinity and specificity as was 
previously demonstrated on another protease (DiMaio et al. 1990;Shuker et al. 




Chapter 5 - Paradigm of Evolutionary Complexity of 
Enzymatic Machinery: Catalysis of the Severe Acute 
Respiratory Syndrome (SARS) coronavirus main Protease 





5.1.1. Expression and enzymatic activities of WT and mutated SARS-CoV 
main proteases 
We have succeeded in obtaining correct DNA constructs encoding all 15 single-, 
one triple-, and five deletion mutants. These GST-fusion constructs were transformed 
into the E.coli BL21 cell strain for over-expression. The results demonstrated that 15 
single-, 1 triple-, ND (Δ1-5), and LHD (Δ293-306) were well expressed and soluble, 
while the CD (Δ278-306), LR (276-290/2G), and LR (276-290/4G) were 
unexpressible. The expressed GST-fusion proteins were purified by using the 
Glutathione Sepharose Affinity column, and the pure mutated main proteases were 
further obtained by an in-gel thrombin cleavage, followed by FPLC gel-filtration 
purification. The SDS-PAGE gel and MALDI-TOF mass checking indicated that all 
recombinant proteins purified by this procedure were homogenous and intact. 
The enzymatic activities of the WT and mutated proteases were measured by use 
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of a FRET-based assay at three different NaCl concentrations. As seen in Figure 1.6, 
based on the enzymatic activity profiles at 0 mM NaCl, all 18 Mpro mutants could be 
divided into four groups. The first group, including Glu288A, Asp289A, Glu290A, 
Arg298A, Gln299A, ND, and LHD, showed dramatic losses of activity, and retained 
less than 10% of the WT proteolytic activity. The second group, containing Asn214A, 
Leu282A, and Cys300A, had significant activity decreases, but still preserved ~30% 
of the WT activity, while the third group, consisting of Thr280A, Gly283A, and 
Ser301A, had no significant activity differences from the WT protease. What was 
interesting was that the replacement of residues Ser284, Thr285, Ile286, and Phe291 
by Ala had given rise to the mutated proteases with enzymatic activities higher than 
that of the WT. Therefore, we constructed a triple mutant with three neighboring 
residues Ser284, Thr285, and Ile286, all mutated to Ala, and remarkably, this led to a 
“super-active” SARS-CoV Mpro, which owned a 3.7-fold enhanced activity. As such, 
we placed Ser284A, Thr285A, Ile286A, Phe291, and the super-active mutants 
together as the fourth group. 
It is also worth noting here that the enzymatic activities of the WT and mutated 
proteases were highly salt-dependent. When 100 mM NaCl salt was introduced, only 
~50% of the enzymatic activities preserved for almost all proteases. If the NaCl salt 
concentration was further increased up to 1050 mM, the residual activities only 
accounted for less than 10% for all proteases, except for the super active mutant, 





Figure 1.5 - Enzymatic activities of WT and mutated SARS-CoV Mpro  
The FRET-based activity assay was carried out by monitoring the increase of the 
emission fluorescence at a wavelength of 538 nm upon the proteolytic cleavage of the 
internally quenched fluorescent pair. For each protease, the enzymatic activities were 
measured at three different NaCl concentrations: 0 mM (grey bars), 100 mM (empty 
bars), and 1050 mM (black bars). Each activity value was the average of four 
independent measurements. Based on these activities, all mutated proteases were 
categorized into four groups, which were boxed and labeled. 
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5.1.2. Dimerization and structural properties 
Dynamic light scattering was used to estimate the molecular weights of the WT 
and mutated proteases at three different NaCl concentrations. As presented in Figure 
2.6, at 0mM NaCl concentration, it could be seen that except for the super active 
mutant with a molecular weight almost identical to that of the WT protease, the other 
mutations all had smaller molecular weights, thus indicating a disruption of the 
dimerization to a certain degree. In particular, the molecular weights of the mutated 
proteases in the first group were averagely ~20 kDa smaller than that of the WT (56.3 
kDa). This observation strongly suggests that these residues might be dominantly 
responsible for enzyme dimerization. Furthermore, it appeared that Asn214A also had 
a much smaller molecular weight (~31 kDa), indicating that Asn214 was also 
important for dimerization. Therefore, at least four regions of the SARS-CoV Mpro 
might be significantly associated with enzyme dimerization, namely, 1) the 
N-terminal residues 1–5 as previously identified (Yang et al. 2003;Chou et al. 2004), 
2) the region around Asn214, 3) the region around residues Glu288-Asp289-Glu290, 
and 4) the C-terminal last helix region around residues Arg298-Gln299. On the other 
hand, the results presented in Figure 2.5 also indicate that statistically, NaCl salt 
within 1050 mM had no significant disrupting effect on enzyme dimerization. In fact, 
for some mutated proteases, high salt concentrations appeared to favour dimerization. 
This is particularly true for the super-active mutant that had molecular weights of ~59 
kDa at 0 mM, ~67 kDa at 100 mM and ~83 kDa at 1050 mM NaCl. The observed 




Figure 2.5 - Molecular weights of WT and mutated SARS-CoV Mpro  
The molecular weights of the WT and all mutated proteases with a protein 
concentration of ~100 μM were measured by dynamic light scattering at three 
different NaCl concentrations: 0 mM (grey bars), 100 mM (empty bars), and 1050 mM 
(black bars). The mutants with significantly decreased molecular weights that may be 
responsible for dimerization were boxed.
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introducing NaCl could result from non-specific aggregation. 
 
5.1.3 Structural properties characterized by CD and NMR 
Far-UV CD spectra were collected for the wild-type and mutated proteases to 
evaluate their secondary structures. As seen in Figure 3.5, although the Ala-mutations 
and fragment deletions induced some changes, the changes were not very significant. 
Therefore, it is very unlikely that a significant change in the secondary structure 
occurred upon mutation and deletion. The tertiary structure of the WT and mutated 
proteases was first assessed by one-dimensional 1H NMR spectrum. As indicated in 
Figure 4a-d.5, similar to the WT protease, all mutants gave rise to several NMR 
resonance peaks at a very up-field region (~1.1-0.5 ppm), indicating that they may 
own a well defined tertiary structures. A detailed examination of the NMR spectra 
revealed that the mutants in the first group plus Asn214A had spectra with sharper 
resonance peaks than the WT protease, consistent with the results that these mutants 
had significantly smaller average molecular weights than the WT because the NMR 
resonance peak width is size-dependent, and a larger protein will give rise to broader 
NMR peaks due to the short T2 (transverse relaxation time) (Wagner 1993;Tugarinov 
et al. 2004). Interestingly, regardless molecular weight estimated by DLS, all mutant 
proteases gave rise to one, but not two, sets of up-field resonance peaks similar to the 
WT, indicating that the monomer-dimer equilibrium is a fast exchange process on the 











Figure 3.5 - Far-UV CD spectra of WT and mutated SARS-CoV Mpro 
The far-UV CD spectra were collected at 20 oC in a 10 mM phosphate buffer at pH 
7.0, containing ~5 μM proteins and 5 mM DTT. The CD spectrum of the WT protease 








Figure 4.5 - Structural 
properties of WT and 
mutated Mpro assessed by 
one-dimensional 1H NMR 
experiments 
One-dimensional 1H NMR 
spectra were acquired at 20 °C 
in a pH 7.0 buffer, containing 
5.5 mM NaH2PO4, and 5 mM 
DTT. The aliphatic side-chain 
regions are shown here for the 
WT and group 1 mutated 
proteases (a);  
WT and group 2 (b);  
WT and group 3 (c);  
WT and group 4 (d);  
The upfield NMR resonance 
peaks resulting from a tight 









In order to gain more detailed insights, WT, ND, E288A, E290A, R298A, Q299A, 
LHD, and STI/A mutants were further 15N-labeled and subjected to HSQC assessment. 
As seen in Figure 5a.5, the HSQC spectra of the WT protease are very broad, and 
only a small portion of resonance peaks are visible, consistent with our previous 
report. This is mostly due to the very large molecular weight for the WT protease in a 
dimer dominant state. Interestingly, the STI/A mutant had a HSQC spectrum (Figure 
5b.5) very similar to that of the WT, indicating that both STI/A and WT proteases 
shared similar structural and dimerization properties. On the other hand, R298A and 
ND mutants, which were shown by DLS to have a monomer-like molecular weight 
(Figure 2.5), suddenly had very dispersed HSQC spectra with many resonance peaks 
detectable (Figure 5c, e.5). This observation indicates that the two mutants were in 
monomer-dominant states that were also well structured. Interestingly, although here 
the LHD mutant also had a well-dispersed HSQC spectrum (Figure 5d.5), the visible 
HSQC resonance peaks were less than those of R298A and ND mutants. Therefore, in 
the current case, it appears that the HSQC line-width was modulated both by the 
average molecular weight resulting from fast inter-molecular monomer-dimer 
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equilibrium, as well as by intra-molecular conformational exchanges. It is very likely 
that although the LHD mutant had a dominant tendency to form a monomer, the 
deletion of the whole last helix may provoke μs-ms conformational exchanges to 
some degree, which caused some HSQC peaks too broad to be clearly distinguished 
form the noise signals. However, when the HSQC spectral level was lowered, it was 
found that most HSQC peaks of the ND, E288A, E290A, R298A, Q299A, LHD, and 
STI/A were almost super-imposable to those of the WT protease, as exemplified by 
Figure 6f.5, in which the HSQC spectra of the R298A and WT proteases were 
superimposed at a lower spectral level. These results, together with CD spectra, 
indicate that it is very likely that within the well-structured regions such as the one 
characterized by the chymotrypsin-fold and the C-terminal extra domain, no dramatic 
change occurred in the secondary and tertiary structures upon mutations and deletions. 
However, the mutations and deletions certainly resulted in minor structural changes as 
well as conformational exchanges on the μs-ms time scale, to different degrees, which 
consequently made some HSQC lines/spots too broad to be detected. 
 
 5.1.4. Unspecific cleavage activity on mutated substrate 
  Here, for the first time we observed the existence of the unspecific cleavage 
activity of the SARS-CoV Mpro by a S1 substrate with the absolutely-conserved P1 
residue Gln mutated to Ala. Figure 6a.5 presents the HPLC profile of the WT 
substrate cleaved by the WT protease, while Figure 6b.5 is the profile of the mutated 
 103 
 
substrate cleaved by the super-active mutant. The results by mass spectrometry 
analysis of the cleaved products confirmed that the cleavage site of the WT substrate 






Figure 5.5 - Structural properties of WT and mutated Mpro assessed by 
two-dimensional 1H-15N HSQC NMR experiments 
Two-dimensional 1H-15N HSQC NMR spectra were acquired for 15N isotope-labeled 
WT and mutated proteases at 20 °C in a pH 7.0 buffer, containing 5.5 mM NaH2PO4, 
and 5 mM DTT. (a) HSQC spectrum for WT main protease, (b) for super-active STI/A 
mutant, (c) for R298A mutant, (d) for last-helix deleted mutant LHD, (e) for the 
N-terminal 5-residue deleted mutant ND, and (f) superimposition of the HSQC spectra 












Figure 6.5 - Unspecific cleavage activity of WT and super-active SARS-CoV 
Mpro  
a) HPLC profile of the cleaved products of the WT substrate by the WT protease for 
ten minutes.  
b) HPLC profile of the cleaved products of the mutated substrate by the super active 
protease for five hours.  
c) Cleavage activity of the WT or super active protease on the WT or mutated 
substrate in the absence (empty bars), and in the presence of 100 mM NaCl (black 
bars): group 1) WT protease on WT-substrate, group 2) super active mutant on 
WT-substrate, group 3) WT protease on mutated substrate, and group 4) super active 
mutated on mutated substrate. 
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However, as seen in Figure 6c.5, the unspecific cleavage on the mutated peptide was 
much slower. Only 19.6% and 50% of the mutated peptide were cleaved by the WT 
and super-active proteases in the absence of NaCl, respectively, after five hours, while 
52.1% and 94.6% of the WT peptide were cleaved within ten minutes in the absence 
of NaCl. It is also interesting to note that the unspecific proteolytic activity is also 
salt-dependent. 
6.2. Discussion 
Unprecedented global and rapid responses have been coordinated to combat the 
newly-emerging SARS disease immediately after its outbreak and so far ~4500 SARS 
related papers were available on PubMed. Due to the central role in the virus 
replication, the SARS-CoV main protease has now been established as a top target for 
the design of anti-SARS drugs and consequently, extensive studies have been reported 
on its structural and enzymatic properties. By a combined approach, with protein 
dissection and biophysical characterization, we first experimentally demonstrated the 
critical role of the extra domain in dimerization and activity of the SARS-CoV main 
protease, and thus proposed it as a new target for inhibitor design. Interestingly, a 
recently reported study identified antibodies that were able to significantly inhibit the 
SARS-CoV main protease activity by targeting its extra domain.  
Although several recently studies have been reported on the dimerization of the 
SARS-CoV main protease (Chou et al. 2004;Hsu et al. 2005b), a systematic 
assessment of this issue is still lacking. To further uncover the regulatory mechanism 
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placed by the extra domain, we initiated a systematic approach to mutate all 15 
extra-domain residues that have close contacts with residues on another protomer, as 
well as to delete the regions that have extensive contacts with the selected 15 residues. 
The results allowed us to identify four regions critical for enzyme dimerization: 
namely the first five residues, the region around Asn214, the region over 
Glu288-Asp289-Glu290, and the region over Arg298-Gln299 on the last C-terminal 
helix. If these regions were mapped back to the dimeric three-dimensional structure of 
the SARS-CoV main protease, a very interesting picture emerges. As seen in Figure 
7a.6, the identified regions critical for dimerization cluster together to form a tertiary 
packing core in the middle of the enzyme dimer. Examination of the packing core in 
Figure 7b.6 from a bottom view discloses more remarkable information. In fact, in the 
core region, only two direct inter-monomer contacts exist between Glu290 of one 
protomer and Arg4 of the other. In this way, the dimerization core residues are joined 
together to form a closed interaction network. It appears that one possible role of the 
identified residues other than Arg4 and Glu290 might be to maintain the correct 
side-chain conformations of the residues Glu290 and Arg4 by interacting with them. 
Indeed, within the same protomer, Asn214 has close contacts with Phe3 and Gln299, 
while Glu288 is in close contact with Lys5. Alternatively, some identified residues 
might contribute to dimerization by interacting with other non-extra-domain residues 
that are not explored in the present study. It is also important to emphasize that 
although the dimer interface appears relatively large (>2000Å2), the single mutation, 
in particular on Glu288, Asp289, Arg298, or Gln299, is sufficient to significantly 
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disrupt enzyme dimerization, and to inhibit the activity. This implies that it would be 
a promising strategy for anti-SARS drugs to design molecules to disrupt enzyme 
dimerization. 
Another striking and surprising result in the present study is the discovery of two 
regions (Ser284-Thr285-Ile286 and Phe291) on which reducing the side-chain 
volumes significantly boosted enzymatic activity. Based on this observation, a 
super-active mutant with a 3.7-fold enhancement of the proteolytic activity was 
engineered, by mutating three residues Ser284-Thr285- Ile286 to Ala. As judged from 
the DLS results and NMR HSQC spectra, the triple-mutant has structural and 
dimerization properties similar to those of the WT protease. This observation thus 
strongly implies that in addition to dimerization, the extra domain might have other 
mechanisms to regulate the catalytic machinery. To the best of our knowledge, it is 
very rare to find that manipulation on regions distinct from the catalytic domain can 
significantly enhance catalytic activity. 
As seen in Figure 8c.5, the two extra-domain enhancing regions are far away 
from the active sites of both protomers. This raises a very interesting question on how 
these regions can achieve regulation on the catalytic machinery, which is far away. 
Possibly, the slight but long-range alterations of structure and dynamics of the 
enzyme, as well as enzyme-solvent interactions upon the mutation may account for 
the observed regulatory effects. Very interestingly, as seen in Figure 8.5, the majority 
of the dimerization residues plus Phe291, Ser284-Thr285-Ile286 are clustered 
together, to form a molecular channel passing through the middle region of the 
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enzyme. Owing to its molecular-scale size, we thus call it a nano-channel. The upper 
wall of the channel appears to have connectivity to the inner cavities, while the two 
ends of the channel are also further connected to the surface cavities of the enzyme 
molecule, which eventually leads to the active site pockets. Remarkably, the Ala 
mutations of the residues Ser284-Thr285-Ile286, which significantly enhanced 
catalytic activity, will remove the bottom wall of the channel. Based on this, we thus 
speculate that this channel might serve as a regulator, sitting in the central region of 
the enzyme, and playing a role in relaying the regulatory effect from the extra domain 
to the catalytic machinery. Certainly, the future determination of the high resolution 
structures of the mutant proteases, such as ND, Arg298A, Asn214, and super-active 
mutant STI/A, may shed light on the molecular mechanism of how the dimerization 
correlates to the activity of the WT protease, as well as why Ala mutations of Ser284, 
Thr285, and Ile286 can dramatically enhance the catalytic activity. Nevertheless, 
understanding the fundamental molecular mechanism underlying these observations 
still remains extremely challenging, because the enzymatic catalysis is not only 
dependent on the static three-dimensional structure, but is also critically modulated by 
the conformational dynamics of the enzyme at every catalytic stage.  
In summary, our study revealed several previously unknown phenomena, which, 
when associated with the coronavirus main protease, highlight the regulatory roles of 
the extra domain on the catalytic machinery. Interestingly, although the evolutionarily 
related picornavirus 3C protease shares basic catalytic machinery with the coronavirus 
main protease, it appears that the latter places its catalytic machinery under extensive 
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regulations by the evolutionarily acquired extra domain. Our results thus illustrate an 
interesting example that shows how nature can nicely engineer a regulatable main 
protease from the picornavirus 3C protease, by simply introducing a domain 















Surface representation of 
the dimeric SARS-CoV 
Mpro structure. 
The residues are colored 
in the same way as in 
Figure 6.  
The nano-channel passing 
through the central regions 
of the enzyme is indicated. 
The two 
Ser284-Thr285-Ile286 
loops from both protomers 
are in close contact with 
each other to constitute the 
bottom wall of the 
channel. b) The bottom 
view of the nano-channel. 
It can be seen that both 
ends of the channel have 
further connectivity to the 
surface cavities that 
eventually lead to the 











Figure 8.5 - Extra-domain 
residues critical for 
dimerization and regulation 
a) Ribbon representation of the 
dimeric SARS-CoV Mpro with 
the residues critical for 
dimerization drawn in the sphere 
mode. The colors show the 
N-terminal 5 residues of 
protomer 1 (yellow), protomer 2 
(green), extra-domain residues of 
protomer 1 critical for dim 
erization (pink), protomer 2 
(blue), active site residues His41 
(red), and Cys145 (light brown).  
b) The bottom view of the above 
structure. The inter-monomer 
contacts between Glu290 of one 
protomer and Arg4 of another 
protomer are indicated.  
c) The residues critical for both 
dimerization and regulation are 
highlighted. The hot pink spheres 
are used to indicate residues 
Ser284-Thr285-Ile286 and 
Phe291 of the protomer, while 
cyan spheres indicate those of 
protomer 2. The nano-channel, 
formed by the dimerization, 
Phe291 and 
Ser284-Thr285-Ile286 residues is 
labeled. 
Protomer 2 Protomer 1 
Protomer 2 
Protomer 1 













Chapter 6 - Mechanism for Controlling Dimer-monomer Switch and 
Coupling Dimerization to Catalysis of the SARS-CoV Main Protease 
 
6.1 Results and discussion 
 
6.1.1. Crystallization and structure determination 
In the present study, we have attempted to crystallize all monomeric mutants 
that we have previously documented, and subsequently, this led to acquiring 
high-quality crystals for the R298AN mutant.  This success thus allowed us to 
determine the first monomeric crystal structure of the SARS-CoV Mpro in the space 
group P21, at a resolution of 1.75 Å (Table 1.6), with one molecule per asymmetry 
unit.  The present observation that the R298AN mutant exists as a monomer in 
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crystal is consistent with the results we previously obtained in solution by the 
gel-filtration chromatography and dynamic light scattering, as well as by the 
analytical ultracentrifuge (see below). The R298AN crystal structure showed that no 
biological dimer unit like that of the WT Mpro could be formed in the unit cell, even 
by considering the crystallography 2-fold symmetry between the adjacent asymmetric 
units (Figure 1.6).  Moreover, the present crystal packing has never been found in 
any previously reported structures of the SARS-CoV Mpro crystallized in various 








Wavelength (Å)     1.0810 
Resolution limit (Å)    50- 1.75 (1.81-1.75) 
Space group     P 21 
 
Cell parameters 
  a (Å)      33.39 
  b (Å)      66.23 
  c (Å)      62.21 
  β (°)         100.77 
  Observed reflections   186691 
  Unique reflections    26899 
  Completeness     99.4% (95%) 
  Redundancy     6.9 (4.5) 
  Linear R-factor    0.067 (0.245) 
  Overall I/(I)     12.3 (2.2) 
  
Refinement 
  Resolution range (Å)    50.0-1.75  
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  R work** (# of Reflections)   0.168 (23600) (cutoff 2.0) 
  Rfree*** (# of Reflections)   0.209 (1452) (cutoff 2.0) 
  rmsd bond lengths (Å)    0.008 
  rmsd bond angles (deg)    1.43 
 
Ramachandran plot 
  Favored, %     89.4 
  Allowed, %     9.4 
  Generously allowed, %    0.8 
  Disallowed, %     0.4 * 
*Only one residue, Tyr 154, is in the disallowed region. This residue is located at the tight 
turn region, which leads to the abnormal dihedral angle.  
**Rwork= Σ ( ||Fp(obs)| - |Fp(calc)||)/ Σ|Fp (obs)|, where Fcalc and Fobs are the calculated and 
observed structure factor amplitudes, respectively. 














Figure 1.6 - Crystal packing of R298AN mutant and comparison with other 
native SARS-CoV 3CLpro structures  
Crystal packing of the R298AN mutant viewed down along a axis (a); and c axis 
(b). In a unit cell, the arrangement of the molecules of the R298A mutant in space 
group P21 (c) is different from the previously reported native SARS-CoV Mpro 
structures in space group C2 (d, h), P43212(e), P21212(f), and P21(g). For the 
native protease structures, two molecules form a biological dimer in the unit cell. 
One molecule is shown in magenta, while the other molecule, related by the 












Figure 2.6 - Sedimentation velocity ultracentrifugation of R298AN mutant  
The sedimentation experiments were carried out with a Beckman Coulter XL-I 
analytical ultracentrifuge at 20 °C and 42,000 rpm, at protease concentrations from 
0.2 to 3 mg/mL. (a) Sedimentation velocity absorbance trace of the R298A mutant 
(1 mg/ml) at 280 nm. (b) Residuals of the experimental fit of the R298A mutant at 
1 mg/mL (29.8 μM). (c) Continuous sedimentation coefficiency distributions at six 
different protease concentrations (from 0.2 to 3 mg/ml). 
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6.1.2. Analytical ultracentrifuge characterization 
To further characterize the actual status of the R298AN mutant in solution, 
analytical ultracentrifuge experiments were carried out to measure sedimentation 
coefficients at six different protein concentrations. Analysis of the sedimentation 
velocity data collected at all these concentrations gave rise to peaks at ~2.8 S, by use 
of the continuous c(s)-distribution model (Figure 2.6).  Moreover, based on the 
continuous c(M)-distribution model, the molecular weights of the R298AN mutant at 
different concentrations were determined to range from 31.1 to 33.7 kDa.   Most 
importantly, even at a protease concentration of up to 3 mg/ml (89.6 µM), no peak 
could be detected at ~4 S, which was expected for the WT Mpro dimer.  The results 
clearly indicate that the R298AN mutant exists as a monomer in solution, completely 
in agreement with the crystallographic result that the R298AN mutant even remained 
as a monomer at the saturation crystallization condition with a protein concentration 
at least higher than that of the initial solution used for crystallization (10 mg/ml).    
 
7.1.3. Structural comparison 
Remarkably, the R298AN mutant still adopts the characteristic architecture 
common to all coronavirus main proteases, with all residues (1–306) well defined in 
the electron density maps as exemplified in Figure 3.6.  However, as seen in Figure 
4a.6, due to the large conformational changes on catalytic domain  and a 40° 
reorientation between the catalytic domain (residues 12–180), holding the entire 
















Figure 3.6 - Simulated-annealing Fo-Fc map (contoured at 3.5 sigma) for 
part of oxyanion loop (138-145) in R298AN structure 
 












Figure 4.6 - Crystal structure of monomeric R298AN mutant 
(a). Complete structures of the mutant R298AN (red) and a native SARS Mpro 
(blue) (PDB code of 2H2Z) superimposed over the catalytic domain (12–180). 
(b). Comparison of the extra domain (200–300) of the two structures. The side 
chains of the mutation site are displayed as sticks. (c). Comparison of the extra 



















Figure 5.6 - Stereoview of significantly perturbed residues within region 
(1-200) of mutant R298AN structure 
These residues are mapped to one protomer (brown ribbon) of the dimeric 
structure (pdb code 2H2Z), and are shown as green dots. Another protomer 
is shown as a violet ribbon and the surface. The active site residues His41 










Figure 6.6 - Quantitative structural comparison between crystal structures of 
mutant R298AN and native Mpro (pdb code 2H2Z)  
(A) RMSD plot for backbone atoms of residues 1–200 superimposed over residues 
12–180. (B) RMSD plot for backbone atoms of residues 180–306 superimposed over 
residues 200–300. (C). RMSD plot for both backbone and side chain atoms of 





substrate binding pocket, and the extra domain (residues 200–306) in the R298AN 
structure, it is impossible to superimpose its full structures with other dimeric Mpro 
structures. However, a domain-based superposition with the structure of an active 
enzyme (PDB code 2H2Z) reveals that three regions undergo radical conformational 
changes in the monomeric R298AN structure: namely, N- and C-termini, and the loop 
(181–199) connecting the catalytic and the extra domains (Figures 5.6 and 6.6).  On 
the other hand, a comparison of the tertiary contact maps of the mutant R298AN and 
the active enzyme (pdb code 2H2Z) structures shows that almost no alteration of the 
packing pattern occurs within the catalytic and the extra domains (Figure 7.6) (Xue et 
al. 2007).  Surprisingly, although the mutation R298AN is located on the extra 
domain (200–300), this domain has a backbone rms deviation of 0.41 Å, much lower 
than 1.08 Å for the catalytic fold (12–190).  It is particularly worth noting that even 
the side-chain orientations of Arg298 in 2H2Z and Ala298 in R298AN are highly 
similar (Figure 4b.6).  Examination of the residue-specific rms deviations indicates 
that while no large change is detected within the extra domain, relatively large 
variations can be recognized within the catalytic fold, in particular, over several loops 
constituting the catalytic site including residues 117–125, 133–144 and 166–169 
(Figures 8c.6 and 8d.6).  Very interestingly, these segments are near to the 











Figure 7.6 - Comparison of contact maps of R298AN (blue) and fully active 
enzyme structure (red).  
(A) Superimposition of the intra-molecular contact map of a native enzyme 
structure (pdb code 2H2Z) over that of the mutant R298AN structure. (B) The 
map of R298AN over that for 2H2Z. The contacts within 8 Å were generated by 









Figure 8.6 - Comparison of active-site conformations  
RMSD plot of the residues 130–150 obtained by overlaying the structure of the 
mutant R298AN with that of a fully active enzyme (pdb code 2H2Z), as well as 
with all available protomer structures carrying the collapsed active site. (A) for 
backbone and (B) for side chain. (C)-(D). RMSD plot of residues 130–150 
obtained by overlaying 2H2Z with the R298AN structure, as well as with all 
available protomer structures carrying the collapsed active site. (C) for backbone 


















Figure 9.6 -Stereoview of interaction network responsible for maintaining 
dimeric structure (pdb code 2H2Z), with one protomer in purple and another 
in cyan 
 
Hydrogen bonds are indicated by cyan dashed lines, hydrophobic interactions by 
red dashed lines, and salt bridges by blue dashed lines. The active site residues 
Cys145 of both protomers are displayed as spheres. Interestingly, it appears that 
Tyr126 is utilized for maintaining dimerization via an aromatic-hydrophobic 
interaction with Met6 of the opposite protomer, as well as for stabilizing the 





6.1.4. How R298AN triggers a mutation from dimmer to monomer switch 
These findings open up an interesting question as to how the R298AN 
mutation can dramatically eliminate dimerization without deconstructing the overall 
3D structural architecture.  Previous characterization suggests that the dimerization 
interface consists of residues from both the catalytic fold and extra domain of the 
SARS-CoV Mpro (Chou et al. 2004;Hsu et al. 2005b;Yang et al. 2003).  Both N- and 
C-termini have been found to play a key role in maintaining the dimeric structure. In 
particular, as shown in Figure 8b.6, the N-terminus (also termed N-finger) not only 
extends beyond the catalytic fold to pack with residues on the extra domain of the 
same protomer, but also forms extensive interactions with residues of the opposite 
protomer. Besides these inter-protomer interactions, two have been documented to 
significantly stabilize the dimeric structure, namely a salt bridge between the side 
chains of Arg4 and Glu290 of the opposite protomer (Chou et al. 2004), as well as a 
hydrophobic-aromatic interaction between the side chains of Met6 and Tyr126 of the 
opposite protomer (Figure 10.6).  Interestingly, mutation of either Met6, or Glu290 
or Arg298 has been demonstrated to trigger the dimer-to-monomer switch of the 
enzyme (Wei et al. 2006).  On the other hand, within the same protomer, a hydrogen 
bond is formed between the side-chain NH2 of Arg298 and the backbone oxygen of 
Met6.  Furthermore, as seen in Figure 10.6, Arg298 is located at the end of the extra 
domain, and folds back to interact with the catalytic fold.  As such, it is likely that 



















Figure 10.6 - Stereoview of dimeric structure (pdb code 2H2Z) with one 
protomer in ribbon and another in surface modes.  
 
The mutation residue R298 is shown as red spheres. The N-terminus of 
protomer A is indicated by green sticks and C-terminus by brown sticks. The 
part of oxyanion loop Ser139-Phe140-Leu141 which is converted into a short 
310-helix in the mutant R298AN structure is labeled and colored in cyan. The 





the N- and extra domain of the same protomer together, and in this way, considerably 
stabilizes the precise positioning and orientation of the N-finger and extra domain, 
which are absolutely essential for dimer formation.  Also very strikingly, it appears 
that the intra-protomer interaction between R298 and Met6 can be further connected 
to the catalytic machinery of the opposite protomer through a two-step relay: an 
inter-protomer hydrophobic-aromatic interaction between the side chains of Met6 and 
Tyr126, followed by an intra-protomer aromatic side-chain interaction of Tyr126 to 
Phe140, an essential component of the substrate-binding pocket (Figure 9.6).  The 
phenyl ring of Phe140 interacts with the imidazole ring of His163 at the bottom of the 
S1 specificity pocket, so as to guarantee that this histidine remains uncharged over a 
wide range of pH values.  Indeed, most likely due to the loss of dimerization, the 
aromatic ring of Tyr126 undergoes a significant reorientation in the monomeric 
R298AN structure. Nevertheless, the interactions shown in Figure 8.6c may only 
represent part of a large network mediating dimerization, and other residues, such as 
Ser147, are further involved in modulating dimerization via a long-range effect.   
Since the R298A mutation will release the constrained N-finger and 
C-terminus, followed by a cooperative switch from dimer to monomer, it is not 
surprising to see large rearrangements over the N- and C-termini, as well as a 40° 
rotation between the catalytic fold and extra domain in the monomeric R298AN 
structure.  The present results reveal that although the dimerization interface may be 
relatively large (>2000Å2) and its affinity high, the network mediating dimerization is 
organized in such a way as to contain many key components.  Disruption of any of 
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these will result in a cooperative switch from dimer to monomer.  This mechanism 
may offer a significant advantage to facilitate the enzyme to act by following an 
association-activation-catalysis-dissociation catalytic cycle, as previously proposed 
(Chen et al. 2005b), or/and under extensive regulation by unknown in vivo binding 
partners.  On the other hand, this also implies that it would be relatively easier in 
future to obtain dimerization inhibitors by designing highly specific bifunctional 
inhibitors for the SARS-CoV Mpro, by linking the protein-protein interactions 
discompeters with the active-site inhibitors. 
 
7.1.5. Why dimerization is essential for catalysis 
The coronavirus main protease shares similar catalytic machinery with the 
picornavirus 3C protease, accomplishing catalytic tasks through a general base 
catalysis mechanism like chymotrypsin (Huang et al. 2004).  However, instead of 
owning a catalytic triad, as found in chymotrypsin, they only possess a catalytic dyad, 
composed of residues His41 and Cys145, with a buried water molecule at the position 
normally occupied by the side chain of Asp, the third member of the catalytic triad 
(Yang et al. 2003;Lee et al. 2005;Lee et al. 2007).  This water molecule, which forms 
three hydrogen bonds with His41, His164, and Asp187, is proposed as a key 
component of the catalytic machinery.  On the other hand, in the 3C protease, the 
extra domain is completely absent, and there is also no evidence to suggest that 
dimerization is required to activate its catalysis.  Therefore, it is of fundamental 
importance to understand how in the SARS-CoV Mpro, dimerization suddenly 
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becomes coupled to catalysis.  
Surprisingly, although the mutation R298A is located at the end of the extra 
domain, extensive structural variations are observed in the catalytic domain, in 
particular the loops encompassing the catalytic site.  This observation is consistent 
with the previous proposal that the active-site loops of the SARS-CoV Mpro are very 
flexible, and thus, are sensitive to a variation in environmental conditions (Yang et al. 
2003;Tan et al. 2005;Lee et al. 2005;Lee et al. 2007).  As seen in Figure 11.6, many 
residues made up of the catalytic machinery undergo significant changes in the 
monomeric R298AN structure.  More specifically, the loop residues over 138–144 
have many more profound changes than other regions, such as the buried water 
molecule and its hydrogen-bonded His41, His 164, and Asp187.  This is logical, 
because the loop residues Gly138-Ser139-Phe140-Leu141 themselves directly contact 
the surface of the opposite protomer.  Similarly, the antiparallel β-sheet (over 
residues 111–129) that surrounds the catalytic machinery also has large 
rearrangements, because many residues, such as Tyr126 on this β-sheet, also have 
direct contacts with the other protomer.  Nevertheless, as shown in Figure 11.7, the 
most distinguishing characteristic in the mutant R298A catalytic machinery is the 
formation of a short 310-helix by residues Ser139-Phe140-Leu141, which instead 
adopt a loop conformation in the active enzyme structure (pdb code 2H2Z).  Most 
importantly, this chameleon conversion abolishes the key stack interaction between 
the rings Phe140 and His163, and significantly twists the conformation of residues 
Gly143-Ser144-Cys145, thus leading to the collapsed substrate-binding pocket and 
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oxyanion hole.  This amazing observation inspired us to examine all available crystal 
structures of the SARS-CoV Mpro.  To our great surprise, the results indicate that in 
the dimeric structures, this characteristic is absent in the active protomers, but can be 
found in the collapsed protomers.  For example, in the dimeric structure (pdb code 
1UJ1), which possesses a dimeric structure with two different protomers, one 
catalytically-active, and another collapsed (Yang et al. 2003), the conformation 
assumed by residues 136–146 in the active protomer is highly similar to that of the 
fully-active enzyme (pdb code 2H2Z), while the conformation in the collapsed 
protomer highly resembles that of the R298AN structure (Figures 12.6 and 8.6).  On 
the other hand, it was also recently shown that the collapsed protomer in the 1UJ1 
structure could be successfully converted to a catalytically active one by removing the 
N-terminal extra residues leftover from the cleavage of the affinity tag (Xue et al. 
2007).  This strongly implies that although within the dimeric enzyme, the flexible c 
catalytic site can be trapped in the collapsed conformations by a variety of 
unfavorable factors.  However, the collapsed enzyme still has the potential to be 
re-inactivated once the unfavorable factors are removed.  By contrast, it appears that 
if dimerization is lacking, the catalytic machinery will be permanently frozen in the 
collapsed state, thus leading to an irreversible inactivation of the enzyme, as observed 
on the R298A mutant, which was previously shown to have no catalytic activity even 
at a very high concentration. 
Compared with the collapsed protomers in the dimeric structures, the 
monomeric R298AN structure also has profound structural changes over other regions 
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critical for catalysis.  For instance, very large changes are also found over residues 
180–200 that form the S2 subsite.  Therefore, to comprehensively assess the features 
of the catalytic machinery, we quantitatively calculate the active-site cavity of the 
R298A and other SARS-CoV Mpro structures.  Interestingly, in the dimeric structure 
(pdb code 1UJ1) in possession of two asymmetric protomers, the active protomer 
without the characteristic 310-helix has a large and deep cavity over the active site, 
similar to that of the fully active enzyme structure (pdb code 2H2Z).  By contrast, 
the collapsed protomer with the characteristic 310-helix has an active-site cavity with a 
significantly reduced volume in the R298AN structure.  More dramatically, the active 
site cavity of the R298AN structure is completely fragmentized (Figure 13a.6). As a 
consequence, the catalytic machinery of the monomeric R298AN mutant no longer 
suits the binding substrates, and leaves no space to accommodate glutamine at the 
substrate analog P1 site and tetrahedral intermediate.   
 
7.2. Conclusion 
The present study reveals that despite its location at the extra domain, Arg298 
is a key component of an integrated networks modulating dimerization.  By use of 
overlapped residues such as Tyr126, dimerization is elegantly coupled with the 
catalysis of the SARS-CoV Mpro.  As a consequence, the mutation of Arg298 not 
only cooperatively eliminates dimerization, but also irreversibly inactivates the 
enzyme, by permanently freezing the catalytic machinery in a collapsed state, 
characteristic of a formation of a short 310-helix from a chameleon active-site loop.  
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The current results not only provide an underlying mechanism to rationalize the 
observation that the catalytic machinery of the SARS-CoV Mpro is under extensive 
regulation by the unique extra domain, but also bear implications for understanding 
the general principles that govern the evolution of the regulatory device for the 

















































Figure 11.6 - Stereoview of substrate-binding pockets of structures of mutant 
R298AN (red) and native enzyme (pdb code 2H2Z) (blue) 
 
Cyan sticks are particularly used to represent the N-terminal two residues Ser1-Gly2 
of the opposite protomer in the dimeric structure (pdb code 2H2Z), which is 
completely lacking in the monomeric R298AN structure. The characteristic 310-helix 
found in the mutant R298AN structure is shown in ribbon mode and labeled. Spheres 
are used to indicate a buried water molecule at the position normally occupied by the 
side-chain of an acidic residue, the third member of the catalytic triad. Interestingly, 
this water molecule, together with its hydrogen bonded residues His41, His164 and 

































Figure 12.6 - Stereoview of conformations over residues 
Ile136-Lys137-Gly138-Ser139-Phe140-Leu141-Asn142-Gly143-Ser144-Cys145 
in different crystal structures  
 
Catalytically inactive R298AN (red), catalytically inactive protomer of 1UJ1 
(green), catalytically inactive 2BX4 (yellow), catalytically inactive 2BX3 (violet), 



















Figure 13.6 - Structural characteristics of R298AN active site 
 
(a) Active-site cavities mapped to the mutant R298AN structure, (b) to the fully 
active native enzyme (pdb code 2H2Z), and (c) to two different protomers of a 
partly active native enzyme (pdb code 1UJ1). Previously, one protomer of the 
structure (pdb code 1UJ1) was characterized to be catalytically active, while 
another was inactive, due to the collapsed substrate-binding pocket and oxyanion 
hole. The characteristic formation of the short 310-helix can be found in the 
monomeric and inactive R298AN structure, as well as in the collapsed protomer, 
but not in the active protomer of a dimeric structure (pdb code 1UJ1). 
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Chapter 7 – Coupling Rigid Body Rotation in the Dimeric 
Structure to Catalysis of the SARS-CoV Main Protease 
STI/A Mutant 
 
7.1. Results   
 
7.1.1. Crystallization and structure determination of the STI/A mutant  
In an attempt to understand the catalysis mechanism of the activity-enhanced 
STI/A mutant, we have solved the crystal structure of this mutant protease in at 2.7 Å 
resolutions. The construct coding of the STI/A mutant was transferred into the E.Coli 
Bl21 (DE3) strain, which expressed the GST-fusion STI/A mutant after the overnight 
culture induced by IPTG. The cells were harvested and sonicated to release the 
GST-fusion STI/A mutant, which was purified by use of glutathione beads. After the 
on-gel thrombin cleavage, the STI/A mutant was separated from the GST tag, and 
subsequently underwent the additional purification steps of gel filtration 
chromatography and ion exchange chromatography. The pure STI/A mutant was 
dialyzed against the buffer (10mM Tris-HCl, 2mM DTT, pH 7.5), and concentrated to 
10mg/ml for crystallization. The hanging drop method was used to set up the 
crystallization screen for the STI/A mutant, using all the reported crystallization 
conditions for the native Mpro (Yang et al. 2003;Tan et al. 2005;Xue et al. 2007;Lee 
et al. 2005;Lee et al. 2007;Hsu et al. 2005a;Hsu et al. 2004).  
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Table 1.7 - Crystallographic data and refinement statistics for the STI/A mutant 
 
  
Data Collection  
 Wavelength (Å)                 1.0810 
 Resolution limit (Å)                 50- 2.7 
 Space group                  P 21 
  
Cell parameters  
 a (Å)                  50.228 
 b (Å)                  96.523 
 c (Å)  67.692 
 β (°)  104.165 
 Observed reflections  553378 
 Unique reflections  17067 
 Completeness  98.1% 
 Redundancy  3.1 
 Linear R-factor  0.086 
 Overall I/σ(I)  10.4 
   
Refinement  
 Resolution range (Å)  20.0-2.7  
 R work** (# of Reflections) 
 0.201 (14384) (cutoff 2 
sigma) 
 Rfree*** (# of Reflections) 
 0.277 (1205) (cutoff 2 
sigma) 
 rmsd bond lengths (Å)  0.008 
 rmsd bond angles(deg)  1.47 
  
Ramachandran plot  
 Favored, %  78.6 
 Allowed, %  19.1 
 Generously allowed, %  0.9 
 Disallowed, %  1.1 * 
*Only six residues, Asn 84 and Tyr 154 of chain A, Asp33, Ala 46, Asn84, and Tyr 
154 of chain B, are in the disallowed region. These residues are located at the tight 
turn region, which leads to the abnormal dihedral angle.  
** Rwork= Σ ( ||Fp(obs)| - |Fp(calc)||)/ Σ|Fp (obs)|, where Fcalc and Fobs are the 
calculated and observed structure factor amplitudes, respectively. 
*** Rfree=as for Rwork, but only for 6% of the total reflections chosen at random and 





After optimization, the stratified rock-like crystals of the STI/A mutant were grown in 
five days, and matured in 15 days under the crystallization condition (6% PEG 6K, 
3% MPD, 5% isopropanol, and 0.1 M Mes, pH 6.0). A single crystal was isolated 
from the stratified rock-like crystals, and sent for data collection at the National 
Synchrotron Light Source (NSLS), crystals were cryoprotected by 20% glycerol in the 
mother liquid. 
The STI/A mutant was crystallized in the space group P21 at a resolution 2.7 Å 
with two molecules in the asymmetric unit. The phase determination was exploited by 
molecular replacement using the native protease structure (PDB code: 1UJ1) as the 
searching model (protomer A only). The mutating residues (STI/A) were modeled 
using the program COOT (Emsley, Cowtan 2004). The two molecules in the 
asymmetric unit formed a biological dimer similar to the native protease. The 
refinement of the model for the STI/A mutant dimer was done in the program CNS. 
The solvent molecules were added into the model using the water_pick model in the 
CNS program. The R factor of the final model with 101 water molecules was 20.1%, 
while the Rfree factor was 27.7%. In the electron density maps, the residues 1A-306A 
and 0B-303B were identified. The Gly(-1)A, Ser(0)A, Gly(-1)B, and the last four 
residues of chain B could not be identified, due to the poorly defined electron 
densities. In the Ramachandran plot of this structure, Asn84 and Tyr154 in protomer 
A, and Asn84, Tyr154, Asp33, and Ala46 in protomer B, were in the disallowed 
regions. Asn84 and Tyr154 were located at the tight turn region of both protomers, 
leading to the abnormal dihedral angles. The parameters and statistics derived from 
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data collection and structure refinement are summarized in Table 1.7.  
 
8.1.2. Kinetic analysis  
The Km, kcat, and kcat/Km parameters of the native protease and the four 
activity-enhanced mutants, including three single mutants (Ser284Ala, Thr285Ala, 
Ile286Ala), and one triple mutant (Ser285Ala-Thr285Ala-Ile286Ala), had been 
determined by a fluorescence resonance energy transfer (FRET) kinetic assay, using a 
fluorescence peptide with a pair of internally quenched fluorescent groups, Dabacyl 
and Edans, in a sequence of Dabcyl-KTSAVLQSGF RKME-Edans (Table 2.7). 
The two single mutants S284A and T285A showed increases of kcat/Km values by 
2.5 folds and 2.3 folds, respectively, as compared to the native protease. The increases 
in kcat/Km value for S284A and T285A are due to an increase in the kcat value and a 
decrease in the Km value. The other single mutant, I286A, showed similar kcat/Km value 
with the native protease, although both the Km and kcat value of the I286A mutant 
dropped by 30%. Strikingly, the combination of the three single mutants generated a 
5.3 fold more active protease mutant, the STI/A mutant, as the kcat value is concern. 
However, the Km value of the STI/A mutant showed an unexpected 1.5 fold increase, 







The values in parenthesis indicate ratio of the Km, kcat and kcat/Km values 









Table 2.7 - Michaelis-Menten Constants 
Protease  Km(μM)  kcat(min-1)  kcat/Km(μM-1min-1) 
Wild type  148.7+52.8 (1)  1.7+0.5 (1)  0.0114+0.0034  (1)  
Ser284Ala  118.3+13.8 (0.8) 3.5+0.3 (2)  0.0292+0.0028  (2.5) 
Thr285Ala  100.4+21.6 (0.7) 2.6+0.4 (1.6) 0.0263+0.0045  (2.3) 
Ile286Ala  99+24.8  (0.7) 1.3+0.3 (0.7) 0.0128+0.0025  (1.1) 




7.1.3. Overall structure comparison between native protease and STI/A mutant 
 The residues S284, T285, and I286 belong to the loop region named STI loop at the 
C-terminus of the main protease (Figure 1a.7). In the native protease dimeric structure, 
the two STI loops interact with each other to form a small region of the dimer interface 
that is isolated from the major region of the dimer interface (Figure 1a.7). The side 
chain of T285 hydrophobically interacts with that of I286 from the opposite protomer 
(Figure 1b.7). The Ala-substituted STI loops still interact with each other in the STI/A 
mutant structure. It is worth noting that even the side chain orientation of 
S284-T285-I286 in the native protease (1UJ1) and A284-A285-A286 in the STI /A 
mutant are highly similar (Figure 2b.7). However, due to the shorter side chain of Ala, 
the distance between the Ala-substituted STI loops changed from 8.4 Å to 5.8 Å, while 
the packing angle of the Ala-substituted STI loops also rotated about 20° (Figure 1b.7). 
Interestingly, the STI/A mutant still adopts a similar architecture common to all 
coronavirus main proteases (Anand et al. 2002;Anand et al. 2003;Yang et al. 2003;Xue 
et al. 2007). If superimposing the individual protomer structure with the native protease 
(PDB code: 1UJ1), the STI/A mutant shows a backbone rms deviation of 0.42 Å, and 
0.53 Å on protomer A and protomer B, respectively. However, if superimposing the 
dimeric structure (two protomers), the STI/A mutant shows a larger backbone rmsd 
value of 0.97 Å (Table 3.7). After a careful comparison of the dimeric packing of the 
STI/A mutant with that of the native protease (PDB code: 1UJ1) (Xue et al. 2007;Yang 






















Figure 1.7  - STI/A triple mutation and its impact on overall structure of 
Mpro 
(a) Native SARS-CoV Mpro structure (PDB code: 1UJ1) (blue) superimposed 
with STI/A mutant structure (red) with catalytic dyad (yellow). (b) Zoom in 
stereo-view of S284-T285-I286 mutating to Ala and resulting in 3Å, the closer 






















Figure 2.7 - Individual domain structures of SARS-CoV Mpro STI/A mutant 
structure (red) superimposed with native Mpro (blue) 
(a) Superimposition of extra domain III of native (PDB code: 1UJ1)and mutant 
structure reveals that the three mutations do not even affect the backbone 
conformation, except for the reduction in side chain volume.  
(b) Superimposition of catalytic fold of native and mutant structure reveals no 





Table 3.7 - Root-mean-square differences (RMSD; in (Å) for superimpositions of the 
structure of the STI/A mutant with those of native protease determined at different pH
 


































  AB:0.521 
 
Superimpositions of structures were done in three groups: protomer A (residues 
3-300), protomer B (residues 3-300), and dimeric structure (both protomer A and B). 
AA corresponds to the superimposition of structures between two protomer A 




























Figure 3.7 – Rigid-body rotation in the dimeric packing of STI/A mutant 
Blue shows the native protease (1UJ1), while red shows the mutant. The 
catalytic dyad (His41 & Cys145) is yellow. In superimposition of protomer A 
from the native and mutant proteases, protomer B of the triple mutant shows a 
longitudinal rotation of 3.3°, measured by the angle among the Cα atoms 
T285_1UJ1_B, His64_1UJ1_B, and A285_STI_B, and a transverse rotation of 
4.8°, measured by the angle among the Cα atoms Asp196_1UJ1_B, 
Trp154_1UJ1_B, and Asp196_STI_B. The residues, H64, Y154, T196, and 
T285, from both native and mutant proteases, are shown in cyan.  
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identified in the STI/A mutant.If superposing protomer A from the native with that of 
the STI/A mutant, protomer B of the STI/A mutant shows a longitudinal rotation of 3.3°, 
for the angle among the Cα atoms T285_1UJ1_B, His64_1UJ1_B, and A285_STI_B, 
and a transverse rotation of 4.8°, for the angle among the Cα atoms Asp196_1UJ1_B, 
Trp154_1UJ1_B, and Asp196_STI_B (Figure 3.7).  
 
7.1.4. Comparison of active sites and substrate-binding regions of the STI/A 
mutant with those of the native Mpro 
In both protomers of the STI/A mutant, the catalytic dyad (His41 and Cys145) 
has a distance of 3.9 Å (protomer A) / 4.2 Å (protomer B) between the NE2 atom His41, 
and the SG atom Cys145. The SG atom Cys145 is also coplanar with the imidazole ring 
His41. These indicate that the catalytic dyad (His41 and Cys145) is in a catalytically 
active state. The catalytic loop (residues 137–144), which is critical for substrate 
binding and catalysis, adopts a loop conformation instead of a 310 helix, as found in the 
inactive form of the protease. Residues Gly143 to Cys145 are in the proper 
conformation to form the oxyanion hole, accommodating the tetrahedral intermediates 
in the catalysis. The phenyl ring Phe140 interacts with the imidazole rings His163 and 
His172, and the side chain of Glu166, to form a well structure pocket to hold the side 
chain of Gln P1 of the substrate (Figure 4.7).  
Upon the rigid-body rotation in the STI/A mutant at pH 6.0, the dimerization 
interface around the active sites on both protomers of the STI/A mutant shows a 
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moderate change compared with the native protease. A slight shift of N-finger (residue 
1 to 7) of the opposite protomer relatives to the active site of the parent protomer was 
observed. More specifically, Ser1 of protomer B moves 4.3 Å (measured between the 
Cα atoms), and provides a new 2.8 Å hydrogen bond with the carbonyl O atom Gly170 
of protomer A, which is located at the substrate binding loop (residues 163–172). 
Interestingly, on the other active site of the dimer, Ser1 of protomer A, being the one 
that is missing in the native protease structure at pH 6.0 due to its high flexibility, is 
able to be identified from the electron density map and interacts with Gly170 of 
protomer B, too (Figure 4.7).    
The rest of the substrate-binding region of both protomers in the STI/A mutant 
structure shows a good agreement with the native structures (Xue et al. 2007;Yang et al. 
2003). Root mean square diviations of the catalytic fold of the STI/A mutant structure, 
compared with that of the native in the catalytically competent conformation, are of 
0.29Å to 0.39Å, showing that the active sites of both protomers of the STI/A mutant are 



























Figure 4.7 – Active site of both protomers of the STI/A mutant in a 
catalytically competent conformation 
 
(a) shows the active site of protomer A of the STI/A mutant compared with that 
of protomer A of the native protease (1UJ1). (b) shows the active site of 
protomer B of the STI/A mutant compared with that of protomer A of the native 
protease (1UJ1). The STI/A mutant is shown in red, while the native protease is 
shown in blue.  
 152 
 
7.2. Discussion  
The SARS-CoV Mpro is a chymotrypsin-like cysteine protease, with one 
catalytic domain, including two β-barrel sub-domains, and one extra helical domain. 
The two molecules of the protease pack against each other at nearly 90°, to form a 
dimer with a dimerization constant in the nM to µM range, as measured by different 
groups under different conditions (Fan et al. 2004;Hsu et al. 2005a;Hsu et al. 
2005b;Graziano et al. 2006b). The SARS-CoV Mpro can only function in the dimer 
status, although it shares a similar chymotrypsin fold to the 3C protease, which is 
functional as a monomer. Without the supportive interactions from the opposite 
protomer, the SARS-CoV Mpro monomer is inactive, due to the catalytic machinery 
being frozen in a catalytically incompetent conformation characteristic by the 
formation of a 310 helix encomponsing the catalytic loop (residues 137–144). Previous 
characterization of the SARS-CoV Mpro suggests that it exhibits a bell-shaped activity 
versus a pH curve, with an optimum pH 7–8 (Chou et al. 2004;Graziano et al. 
2006a;Fan et al. 2004). The activity of the SARS-CoV Mpro at pH 7.5 is about 2~6 fold 
higher than that at pH 6.0, as measured with different substrates. The activity decrease 
is not due to the misfolding of the protease under pH 6.0, since the proteases adopt a 
well-defined tertiary structures within the pH range from 5.9 to 9.0 (Hsu et al. 
2005a;Yang et al. 2003;Tan et al. 2005).  
In the native structure at pH 6.0, only the active site of protomer A adopts a 
catalytically competent conformation, while the active site of protomer B represents a 
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collapsed conformation at the S1 substrate binding site and the oxyanion hole. Residue 
Ser1 plays an important role in the asymmetricity of the active sites in both protomers. 
Ser1 of protomer B participates in interactions to the active site of protomer A, and 
keeps them in a catalytically competent conformation. On the contrary, Ser1 of 
protomer A could not be detected in the electron density map, perhaps due to its high 
flexibility. With its high flexibility, the interaction between Ser1 of protomer A and the 
active site of protomer B may become weaker, and lead to the collapse of the active site 
of protomer B. Ser1 may exist as two states in the native structure at pH 6.0, in which 
one is more stable, and the other is more flexible. To maintain the proper conformation 
of the active site in one protomer, the stability of the other active site in the other 
protomer may need to be sacrificed, as shown by the collapse of the active site and the 
not defined of Ser1 and Gly2 of the opposite protomer. However, in the structures of 
the native protease at a high pH (7.6 or 8.0), the active sites of both protomers adopt a 
catalytically competent conformation with Ser1 of both protomers well defined (Yang 
et al. 2003).  
However, the mechanism of the pH-dependent catalysis of the SARS-CoV 
Mpro has been proposed to be correlated with the protonated-deprotonated status of the 
catalytic residue His41, and the stability of the active site pocket. The rigid-body 
rotation in the dimeric packing of the SARS-CoV Mpro at a low pH (such as 6.0) (1UJ1) 
compared with that at a high pH (such as 7.6) (1UK3) has also been proposed to play a 
role in the mechanism. In the superposition of protomer A of the dimeric structure at pH 



















Figure 5.7 – Rigid-body rotation in dimeric packing of the SARS-CoV Mpro 
at pH 7.6 relative to pH 6.0 
 
The blue shows the native SARS-CoV Mpro at pH 6.0 (1UJ1), while the purple 
shows the structure at pH 7.6. The catalytic dyad (His41 and Cys145) of the 
protomer B is shown in yellow. In superimposition of protomer A from the 
SARS-CoV Mpro at pH 6.0 and 7.6, protomer B of the structure at pH 7.6 shows 
an anti-clockwise rigid-body rotation of 8.7°, measured by Cα from residues 
T285_1UK2-S123_1UK2-T285_1UJ1. Residues (T285 and S123) from both 




(Figure 5.7). Besides the rigid-body rotation, conformational changes are also found on 
the loop encompassing residues 190–196 and residues 160–174 as a result of the pH 
change. Residue His is usually believed to be responsible for a pH-dependent 
conformational switch at a pH range from 6.0 to 8.0, since the pKa value of His is 
around 6.4 in a solvent-accessible environment. There are eight His residues in the 
SARS-CoV Mpro, four of them (His41, His163, His164, and His172) located at the 
catalytic pocket, two of them (His64 and His80) located at domain I, another (His134) 
located at domain II, and the last one (His246) located at the extra domain. When 
comparing the conformations of these His at the structures of the SARS-CoV Mpro at 
pH 6.0 and 7.6, the imidazole rings of the two His residues, His64 and His134, change 
dramatically. Both His64 and His134 are in a solvent-accessible region, indicating that 
their pKa value should be around 6.4. More specifically, the imidazole ring His64 is 
located far away from the dimer interface of the SARS-CoV Mpro, and adopts different 
conformations in the native structure at pH 6.0 and pH 7.6, and the STI/A mutant as 
well as other SARS-CoV Mpro structures solved at pH 6.0 (Figure 6b.7). His134, 
however, that is near the loop encompassing residues 190–196, only adopts two 
conformations at pH 6.0 and pH 7.6 (Figure 6c.7). Therefore, it is possible that His134 
may play a key role in mediating the pH-dependent conformational change of the 
SARS-CoV Mpro in the pH range from 6.0 to 7.6 (Figure 6a.7).  
Strikingly, such rigid-body rotation is also found in the dimeric packing of the 


















Figure 6.7 – His network in dimeric structure of SARS-CoV Mpro 
 
The three crystal structures of the SARS-CoV Mpro at pH 6.0 (blue), at pH 
7.6 (purple), and the SARS-CoV Mpro STI/A mutant (red), are superimposed 
(a). The catalytic residue His 41 (yellow), and the other seven His residues 
(cyan) are shown as spheres. The imidazole rings of His64 adopt different 
conformations over three structures (b). At the same time, the imidazole rings 


















Figure 7.7 – Dimeric packing of STI loop in SARS-CoV Mpro structure at 
pH 6.0 and 7.6 and STI/A mutant 
The STI loop of the three crystal structures of the SARS-CoV Mpro at pH 6.0 





If we compare the rigid-body rotation in the STI/A mutant structure and the native 
Mpro structure in high pH, it suggests that the rigid-body rotation in the STI/A mutant 
structure follows the same trend as that in the native Mpro structure at a high pH, as 
viewed from the packing of the STI loops of both protomers (Figure 7.8). The 
aarrangment of the STI loops rotates of about 40° in the native structure at high pH, 
while that in the STI/A structure rotates of about 20°.  The conformational changes 
between the active sites and the N-terminus and C-terminus of the opposite protomers 
are similar. The enzyme kinetic studies show that the STI/A mutant is a super-active 
protease with a 3.6 fold increase in terms of kcat/Km value, which is mainly contributed 
by the 5.3 fold increase in kcat value. 
Here, a very interesting question arises: how does the rigid-body rotation on the 
dimeric interface of the Mpro facilitate enzyme catalysis? One possibility is that the 
rigid-body rotation in the dimeric structure of the protease changes the interactions 
between the two protomers at the dimeric interface, especially these around the active 
site. The slight conformational changes may facilitate the structural changes (which are 
essential in catalysis) during the catalytic process. The other possibility may be that the 
rigid body rotation may enhance the association-dissociation constants of the protease 
in solution. Chen et al. suggest that the enzyme follows an 
association-activation-catalysis-dissociation catalytic cycle during catalysis (Chen et al. 




8.3. Future work 
In future, in order to understand the relationship between the Ala mutations on the STI 
loop and the association-dissociation cycle of the protease, it is very interesting to 
quantify the association-dissociation constant of the STI/A mutant. This may enhance 
our knowledge of the dimerization mechanism of the protease. In addition, it is very 
interesting to study the profile of the pH-dependent activity of the STI/A mutant, as 
well as the crystal structure of the STI/A mutant in a high pH, both of which may 
explain why the STI/A mutant shows a higher activity than the native one, even at a 
high pH. Meanwhile the mechanism of the pH-dependant conformational change of the 
protease is also worth studying. We could mutate the suspect HIS residue to ALA, and 
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Appendix A  
Brief introduction to enzyme kinetics 
 
Enzymes can accelerate the reaction rate by favoring or enabling a different 
reaction pathway with lower activation energy. The kinetics of the enzyme-catalyzed 
reaction is different from those of a typical chemical reaction. In enzyme kinetics, if 
the initial concentration of the enzyme [E]0 is much lower than the concentration of 
the substrate [S], the initial rate v of the product formation increases linearly with [S], 
while [S] is relatively low. But as [S] increases, this relationship begins to break down, 
and v increases less rapidly than [S], until v approaches the limiting value Vmax. 
In 1913, Michaelis and M. L. Menten proposed the famous enzymatic mechanism, 
known as the Michaelis-Menten mechanism (Eq. 1).  
M catK kE S ES E P⎯⎯⎯→+ ⎯⎯⎯→ +←⎯⎯  Eq. 1 
The catalytic reaction is divided into two processes. First, the enzyme and the 
substrate combine to form an enzyme-substrate complex—ES. This step is assumed to 
be rapid and reversible, with no chemical changes taking place. Then, the ES complex 
dissociates into two parts—E (enzyme) and P (product). The second step is a chemical 
reaction step with a first-order rate constant Kcat (the turnover number). The rate 
equations are shown below (Eqs. 2 and 3). 










max 0[ ]catV k E=  Eq. 3 
KM is the Michaelis constant. When [S] =KM, from the equation above,  
max
2
VV =  Eq. 4 
The constant kcat is often called the turnover number of the enzyme, because it 
represents the maximum number of the substrate molecules converted to products per 
active site per unit time, or the number of times the enzyme “turns over” per unit time. 
In the simple Michaelis-Menten mechanism, kcat is simply the first-order rate constant 
for the chemical conversion of the ES complex to the EP complex. For a more 
complicated reaction, kcat is a function of all the first-order rate constants, and it 
cannot be assigned to any particular process.  
In the simple Michaelis-Menten mechanism, KM may be treated as the true 
dissociation constant of the ES enzyme-substrate complex. However, in the more 
complicated reactions, KM is an apparent dissociation constant that may be treated as 
the overall dissociation constant of all enzyme-bound species.  
kcat/Km represents the apparent second-order rate constant, which refers to the 
properties and the reactions of the free enzyme and the free substrate. The reaction 





=  Eq. 5 
The enzyme kinetics data can by analyzed by a Lineweaver-Burk plot, which can 
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detect any deviations from ideal behavior. In this plot, the reaction rate can be 
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Nuclear Magnetic Resonance (NMR) spectroscopy  
 
Basic theory of Nuclear Magnetic Resonance (NMR) spectroscopy  
Nuclear Magnetic Resonance (NMR) spectroscopy was not recognized as a 
standard method to study the biological macromolecules structure until the first 
globular protein structure was determined by Kurt Wüthrich (Wuthrich et al. 1968), 
who was awarded a Nobel Prize in Chemistry for this work in 2002.  
 
NMR phenomenon 
Nuclear Magnetic Resonance (NMR) is a phenomenon that occurs when nuclei in 
a static magnetic field are exposed to a second oscillating magnetic field and NMR is 
a source of angular momentum intrinsic to the different nuclei. The nuclei can be 
classified into three groups based on their spin numbers, I. The first group, with I 
equal to 1/2, 3/2 or 5/2, has an odd mass number and an even or odd atomic number. 
The second group, with I equal to zero, has even mass numbers and even atomic 
numbers. The third group, with I equal to integer (1, 2, 3), has even mass numbers and 
odd atomic numbers. The nuclei with the spin number I = 0 are NMR inactive, while 
the nuclei with the spin number I > 1/2 are NMR-active, but this is very difficult to 
detect. Only the nuclei with the spin number I = 1/2 are NMR-active, and in which it 
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is easy to observe the NMR phenomenon.  
The nuclear magnetic moment (μ) is given by Eq. 7 
       μ=γIh                                             Eq. 7  
The gyromagnetic ratio (or magnetogyric ratio) γ is a proportionality constant that 
determines the resonant frequency of the nucleus for a given external field, and h is 
the Plank’s constant. There are (2I+1) possible orientations for a nucleus of spin I in a 
magnetic field. For example, a nucleus of spin 1/2 should have only two possible 
orientations (2*1/2+1=2), either parallel or antiparallel to the external field. The 
number of the nuclei oriented in parallel to the external field exceeds the number of 
nuclei oriented antiparallel, because the former are in a lower energy state. The 
different populations between the two energy states follow the Boltzmann 
distribution.  
For the production of an NMR signal, the spins have to be excited from the 
equilibrium configuration with the lowest energy. When a proton is irradiated at the 
correct frequency (ω0) by a radio frequency (RF) pulse, it will absorb the energy and 
be excited from a lower energy state to a higher one. In addition, if this energy is at 
the right frequency, it will cause M0 to rotate away from its equilibrium orientation. 
Furthermore, if the RF pulse (also called the 90° pulse) lasts for long enough and its 
amplitude is high enough, the absorbed energy will enable M0 to move entirely into 
the transverse plane (xy plane), without any magnetization along the z axis. Now the 
net magnetization is produced on the xy plane (Mxy), because the RF pulse has forced 
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all the individual magnetic moments of the protons together, which characteristically 
possess phase coherence immediately after the 90° pulse. When the 90o pulse stops, 
the individual nuclear spins will start to return to their equilibrium state along z axis, 
and the phase coherence is lost. The net magnetization at the Mxy plane starts to rotate 
along B0, again, and the protons will emit the extra energy at a Larmor frequency. 
This event can be captured as a current induced into a coil, tuned to the precession 
frequency, and placed perpendicular to the transverse plane. This produces the NMR 
signal called free induction decay (FID). Hence, the NMR absorption is a 
consequence of the transitions between the energy levels simulated by applied radio 
frequency (RF) radiation.  
 
Relaxation  
When the RF pulse stops, the xy magnetization may return eventually to the 
thermal equilibrium along the z axis. The duration of this event is called relaxation. In 
the Bloch theory of relaxation, equilibrium is assumed to be approached exponentially. 
Thus magnetization will be represented as:  
0
1
Z ZdM M M
dt T








= −  Eq. 10 
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Where M represents the net magnetization; x, y, and z represents the directions of the 
net magnetization, T means the relaxation time.  
 
Longitudinal relaxation (T1) 
T1 is called the longitudinal (or spin-lattice) relaxation. After a 90o pulse, the 
magnetization shifts from the z axis to the xy plane. After longitudinal relaxation T1, 
the z magnetization reappears.   
 
Transverse relaxation (T2) 
When the magnetization is on the xy plane, there is a phase coherence between 
the spins in the transverse plane. Loss of this phase coherence due to mutual exchange 
of the spin energies will give rise to T2 relaxation.  
 
Chemical shift 
Chemical shift is a basic parameter of a nucleus in NMR spectroscopy. It is 
generally denoted as δ, given by Eq. 11, where V represents the precession frequency, 





−δ = ×  Eq. 11 
In protein NMR spectroscopy, the internal reference is normally D2O. The 
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chemical shift is a very precise representation of the chemical environment of a 
nucleus. In a well-defined protein structure, the nuclei, even of the same elements, 
often have different chemical shifts, due to different chemical environments. This 
facilitates a basic principle to distinguish and recognize the different peaks in an 
NMR spectrum. 
 
Nuclear Overhauser Effect (NOE) 
The Nuclear Overhauser Effect (NOE) is the change in the NMR signal intensity 
of a nucleus when its spin system is perturbed by another nucleus. Actual physical 
connection is not required. The only requirement for the NOE effect is that the spatial 
distance between two nuclei should be less than 5 Å. In theory, any two nuclei 
approaching each other within 5 Å can produce an NOE in NMR spectrum. By 
matching all the NOE information with the protein sequence, a tertiary structure 











The first protein crystals (hemoglobin) were grown over 150 years ago. This 
discovery opened up the view of proteins at the atomic level. Since then, X-ray 
crystallography has become the major technology for the determination of protein 
tertiary structure.  Among 38,620 protein structures in the Protein Data Bank (PDB) 
(access on September 5, 2006), more than 80% of the protein structures were solved 
by X-ray crystallography (Berman et al. 2000). 
 
Crystallization  
Crystallization of proteins includes three stages: nucleation, growth, and cessation 
of growth.  
Nucleation is initiated in a super-saturated protein solution. The protein 
molecules come together and form a thermodynamically stable aggregate. A critical 
parameter for the upgrade from an aggregate to a crystal is the size of the aggregate. 
Only when it exceeds a certain size limit is an aggregate able to grow into a crystal. It 
is generally believed that the precipitant agents play a critical role in the growth size 
of aggregates. Each crystal can only grow in one or several precipitant conditions. 
When the size of the crystal is sufficient for X-ray diffraction, the crystal can be 
harvested and frozen in liquid nitrogen for storage. 
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The mechanism of protein crystallization is still unclear. There are many factors 
that may affect protein crystallization, such as pH, protein concentration, precipitant 
and ionic strength. Therefore, it is common practice to use the sparse matrix method 
for exploring a large number of trial conditions. The most common methods for 
screening of crystallization conditions are: the hanging drop vapor-diffusion, the 
sitting drop vapor-diffusion, and the dialysis and batch methods. These methods allow 
screening of proteins in numerous crystallization conditions, with a relatively small 
amount of protein sample, e.g. 1 ul for each condition. Currently, with the new 
development of solution dispensing techniques, only 1nl is required for each condition, 
with help of a robotic system.  
However, the diffracting quality of the protein crystal obtained directly from 
screening methods is usually not good enough for X-ray diffraction. Optimization of 
the crystallization condition is necessary. In fact, the high quality protein crystal could 
be obtained with minor modifications of the crystallization conditions, e.g. pH, 
precipitants and additives.  
Sometimes, protein crystals do not diffract well, even if the thousands of 
crystallization conditions have been exploited. There is no always an evident 
explanation for the diffraction. However, some post-crystallization methods, such as 
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The first prerequisite for solving a protein structure by X-ray crystallography is a 
well-ordered protein crystal that can diffract X-rays robustly.  
 
Crystal system 
The crystal systems are a grouping of crystal structures according to the axial 
system used to describe their lattice. Each crystal system consists of a set of three axes 
in a particular geometrical arrangement. There are seven unique crystal systems, in 
order of decreasing symmetry, are cubic hexagonal, tetragonal, rhombohedral (also 
known as trigonal), orthorhombic, monoclinic and triclinic (Figure 1.c).  
 
The Bravais lattices 
The Bravais lattices are the crystal systems combined with the various possible 
lattice centerings. They describe the geometric arrangement of the lattice points, and 
thereby the translational symmetry of the crystal. There are 14 unique Bravais lattices 
in three dimensions. Each Bravais lattice refers a distinct lattice type (Figure 1.c). 
The lattice centerings are: 
Primitive centering (P): lattice points on the cell corners only 
Body centered (I): one additional lattice point at the center of the cell 
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Face centered (F): one additional lattice point at center of each of the faces of the 
cell 
Centered on a single face (A, B or C centering):  one additional lattice point at 
the center of one of the cell faces. 
 
Point and space groups 
The crystallographic point group is the mathematical group comprising the 
symmetry operations that leave at least one point unmoved and that leave the 
appearance of the crystal structure unchanged. These symmetry operations can 
include reflection, which reflects the structure across a reflection plane, rotation, 
which rotates the structure a specified portion of a circle about a rotation axis, 
inversion which changes the sign of the coordinate of each point with respect to a 
center of symmetry or inversion point and improper rotation, which consists of a 
rotation about an axis followed by an inversion. Rotation axes (proper and improper), 
reflection planes, and centers of symmetry are collectively called symmetry elements. 
There are 32 possible crystal classes. Each one can be classified into one of the seven 
crystal systems. 
 
The space group of the crystal structure consists of the translational symmetry 
operations in addition to the operations of the point group. These include pure 
translations which move a point along a vector, screw axes, which rotate a point 
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around an axis while translating parallel to the axis, and glide planes, which reflect a 
point through a plane while translating it parallel to the plane. There are 230 distinct 
space groups, but only 64 non-ceutrosymmetric space groups in the protein crystals. 
 
X-ray diffraction 
X-rays are electromagnetic waves with relatively small wavelengths (1.5418Å for 
the radiation from in-house X-ray machine and 0.8~1.8Å for that from synchrotron), 
which interact with electrons in a crystal, and get scattered in all directions. These 
scattered X-rays provide the specific information on the electrons that diffract them.  
 
Structure determination 
The common methods to determine a crystal structure are multiple isomorphous 
replacement (MIR), multi-wavelength anomalous dispersion (MAD), or 
single-wavelength anomalous dispersion (SAD). These methods obtain the phase 
information by employing one or several subsets of heavy atoms. In MIR, the native 
crystals are required to be soaked in at least two types of “heavy” atoms. Meanwhile, 
in MAD, one type of heavy atom, Selenium, is introduced into the crystal replacing 
the sulfur atom in residue Met by growing the host cell under the Selenium-rich 
medium; in this method, at least two datasets are required to be collected under the 
different wavelengths of X-rays.  
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Meanwhile, a simpler method called Molecular Replacement (MR) can be used to 
solve the phase problem in structure determination, when a structure of any 
homologous protein is known. This method is becoming more common, since more 
and more protein structures are available through the Protein Structure Genomic 
Projects. 
 
Molecular replacement  
For molecular replacement (MR) method, there is no need for soaking or 
selenium-Met substitution, and more importantly, there is no restriction on resolution 
or molecular weight. Just one complete diffraction dataset is sufficient. The only 
requirement is the availability of a suitable homologous protein structure. The 
homologous protein structures could be crystal structures, NMR structures or models 
obtained by homology modeling. Therefore, MR method is very useful in determining 
the tertiary structure of mutated proteins when the wild-type protein structure is 
known.   
Molecular Replacement was first described by Rossman. There are numerous 
computer programs (AMoRe, MolRep, Phaser and EPMR) available to solve the 
protein structure by MR through different approaches. The most common technique is 
to search using the Patterson function (Eq.12), where Fh is the structure factor. The 
Patterson map is a summation of |Fh|2 without the phase information. The peaks of the 
Patterson map mean the inter-atomic distance. There would be N*N-N peaks in a 
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Patterson map.  
2
( )




= π∑  Eq. 12 
A Patterson map can be considered as a fingerprint of a protein structure with the 
intra-molecular vectors as the finger swirls. Therefore, the alignment of the crystal 
diffraction dataset with a homology structure can be simplified to a correlation search 
of two Patterson maps.  
The basic MR is divided into four steps, although the details may vary between 
different computational programs:  
1. The homology model structure is converted into a set of structure factors, and a 
model Patterson map is computed from these structure factors. As the centre of 
mass is set as the origin, the model is rotated until the principal axes of inertia are 
parallel to the orthogonal axes [(1 0 0), (0 1 0) and (0 0 1)]. Finally, a P1 box is 
generated to accommodate the model.  
2. The observed Patterson map is computed from the diffraction data.  
3. The model Patterson map is rotated and translated. When the model is oriented 
correctly and placed in a proper position in the unit cell, the two Patterson maps 
(model and observed) should be more or less similar. 




Refinement of initial model 
A model generated with the MR method is usually not optimal. The structure 
needs to be refined in order to obtain a set of atomic coordinates that best correspond 
with the observed data.  
Refinement is a process of adjusting the model to find a better agreement between 
the calculated and the observed structure factors, using the least-square method, or 
molecular thermal dynamics. There are two factors, R-factor and Free R-factor that 
are monitored during refinement. R-factor is the agreement index between the 
calculated and observed structure factors. The Free R-factor uses exactly the same 
equation as the R-factor, but is only calculated over a subset of reflections (10% or 
1000 reflections), referred to as the Test set. These reflections are not used in the 
refinement of the model, and so provide an independent indication of the quality of 
the model. The Free R-factor indicates whether the calculated structure is overfitting 
or not. Normally, a PDB-qualified structure should have an R-factor below 30%, an 
Rfree-factor also below 30%, and fine stereo-chemical parameters.  
 
